Modelling extended SSD and large field dosimetry for Total Body Irradiation. by Duncan-Gelder, Phillip
Modelling extended SSD and large field
dosimetry for Total Body Irradiation
Phillip Duncan-Gelder
A thesis submitted for the degree of Master of Science
at the University of Canterbury, Christchurch, New Zealand.
April 2020
Abstract
This thesis describes modelling of the extended source to surface distance (341 cm and 432.6 cm SSDs)
Total Body Irradiation technique used at Christchurch Hospital. Measured results are compared with
manual and commercial treatment planning calculated results using both simple block phantom and
complex anthropomorphic phantom setups.
A Phantom Mobility Device was developed and validated in order to improve upon the simple block
phantom measurement technique in terms of both measurement speed and accuracy. The device was
implemented and used to measure dose profiles and tissue phantom ratios for comparison to treatment
planning system results.
Modelled results from the Monaco treatment planning system were calculated by a specifically-
developed approach to the use of the software. Results from the simple block-type phantom incorporated
both Monte Carlo and Collapsed Cone Convolution algorithms with these results qualitatively compared.
The Monte Carlo algorithm was found to be noisy at extended SSD and therefore only the Collapsed
Cone Convolution algorithm was used for the more complex anthropomorphic phantom.
Linear accelerator measurements were conducted to mirror the modelled results in terms of setup
geometry so direct comparisons could be made. Wall scatter and monitor unit drift were also measured
to correct for the inherent uncertainties these quantities introduce to aid comparisons with treatment
planning modelled results.
Dose difference at various points were used as a metric for comparing the agreement between mea-
sured and modelled results. The feasibility of using Monaco as a treatment planning system was shown
by block-phantom comparisons being clinically acceptable over a wide range of depths and distances
off-axis, with minimal constraints. Whilst clinical use of Monaco could not be fully established due
to limitations in the data attained from anthropomorphic phantom measurements, a description of
proposed improvements to guide future work are described.
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viii
5.3 Profile symmetry graphs determined using data measured on T1 calculated using two
different methods. (a) The zeroed IEC 60976 standard given by Eq. 5.2. (b) The
symmetry from the right half of the field minus the left half normalized to the right half
of the field. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
5.4 Profile symmetry graphs determined using data measured on T2 calculated using two
different methods. (a) The zeroed IEC 60976 standard given by Eq. 5.2. (b) The
symmetry from the right half of the field minus the left half normalized to the right half
of the field. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
5.5 Experimental set up of wall scatter measurements. (a) Shows the chamber set up with
the retort stand, maximum displacement markings and guide lines for the placement of
lead bricks in-front of the chamber. (b) An example measurement of wall scatter with
the lead bricks placed along the guide lines. . . . . . . . . . . . . . . . . . . . . . . . . 53
5.6 T1 Photon energy from points along the wall in the radiation field projected onto the wall
as received by the detector at SMD. (a) With detector at CAX position. (b) Detector
at 25 cm off-axis. (c) Detector 50 cm off-axis. (d) Detector 75 cm off-axis. (e) Detector
100 cm off-axis. This model is symmetrical on both axes. . . . . . . . . . . . . . . . . . . 56
5.7 T2 Photon energy from points along the wall in the radiation field projected onto the wall
as received by the detector at SMD. (a) With detector at CAX position. (b) Detector
at 25 cm off-axis. (c) Detector 50 cm off-axis. (d) Detector 75 cm off-axis. (e) Detector
100 cm off-axis. This model is symmetrical on both axes. . . . . . . . . . . . . . . . . . . 57
5.8 Dose normalized from previous commissioning data to the output point for various OADs
and depths, plotted against OAD and depth for (a) T1 treatment room and (b) T2
treatment room. Profiles and TPRs are shown by these 3D plots with uncertainty bars
(95 % confidence interval) plotted for each measured point in black. . . . . . . . . . . . 58
5.9 Charge rates from PMD measurement normalized to the output point for various OADs
and depths, plotted against OAD and depth for (a) T1 treatment room and (b) T2
treatment room. Profiles and TPRs are shown by these 3d plots with uncertainty bars
(95 % confidence interval) plotted for each measured point in black. . . . . . . . . . . . 60
5.10 Film cut methodology with consistent orientation using labels and numbering at the
upper left hand corner of each film. (a) Shows the numeric labelling of calibration film
where numbers corresponded to the increments in dose, (b) shows the labelling of the
measurement film which labelled the slice number and direction the wall was facing for
the film closest to the wall. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
5.11 Film measured depth doses in RANDO in (a) T1 treatment room and (b) T2 treatment
room. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
ix
6.1 T1 Profiles for depths (a) 2 cm (b) 5 cm (c) 10 cm (d) 20 cm, normalized to the point
where output was measured. Profiles, simulated in Monaco (blue), measured with the
PMD (red), and compared by DD (orange). Uncertainty bars represent 95 % confidence
intervals. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
6.2 T1 Profiles for depths (a) 30 cm (b) 40 cm (c) 50 cm (d) 60 cm, normalized to the point
where output was measured. Profiles simulated in Monaco (blue), measured with the
PMD (red), and compared by DD (orange). Uncertainty bars represent 95 % confidence
intervals. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
6.3 T1 TPRs for OADs (a) 0 cm (b) 10 cm (c) 20 cm (d) 30 cm (e) 40 cm (f) 50 cm, normalized
to the point where output was measured. TPRs simulated in Monaco (blue), measured
with the PMD (red), and compared by DD (orange). Uncertainty bars represent 95 %
confidence intervals. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
6.4 T1 TPRs for OADs (a) 60 cm (b) 70 cm (c) 80 cm (d) 90 cm (e) 100 cm, normalized to the
point where output was measured. TPRs simulated in Monaco (blue), measured with the
PMD (red), and compared by DD (orange). Uncertainty bars represent 95 % confidence
intervals. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
6.5 T2 Profiles for depths (a) 2 cm (b) 5 cm (c) 10 cm (d) 20 cm, normalized to the point
where output was measured. Profiles simulated in Monaco (blue), measured with the
PMD (red), and compared by DD (orange). Uncertainty bars represent 95 % confidence
intervals. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
6.6 T2 Profiles for depths (a) 30 cm (b) 40 cm (c) 50 cm (d) 60 cm, normalized to the point
where output was measured. Profiles, simulated in Monaco (blue), measured with the
PMD (red), and compared by DD (orange). Uncertainty bars represent 95 % confidence
intervals. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
6.7 T2 TPRs for OADs (a) 0 cm (b) 10 cm (c) 20 cm (d) 30 cm (e) 40 cm (f) 50 cm, normalized
to the point where output was measured. TPRs, simulated in Monaco (blue), measured
with the PMD (red), and compared by DD (orange). Uncertainty bars represent 95 %
confidence intervals. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
6.8 T2 TPRs for OADs (a) 60 cm (b) 70 cm (c) 80 cm (d) 90 cm (e) 100 cm, normalized to
the point where output was measured. TPRs, simulated in Monaco (blue), measured
with the PMD (red), and compared by DD (orange). Uncertainty bars represent 95 %
confidence intervals. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
6.9 Dose differences between film measured and Monaco modelled depth doses for (a) T1
treatment room and (b) T2 treatment room. . . . . . . . . . . . . . . . . . . . . . . . . 79
A.1 Solid water set up for up to 30 cm depth. . . . . . . . . . . . . . . . . . . . . . . . . . . 89
A.2 Solid water and water block set up for measurement depths greater than 30 cm. . . . . . 89
x
List of Tables
4.1 T1 Table of Monaco entrance (ENT) and exit (EXIT) doses (in Gy) for various points
where diodes were placed. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
4.2 T2 Table of Monaco entrance (ENT) and exit (EXIT) doses (in Gy) for various points
where diodes were placed. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
4.3 T1 Monaco Midline doses (in Gy) for various regions determined for both left and right
fields and averaged. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
4.4 T2 Monaco Midline doses (in Gy) for various regions determined for both left and right
fields and averaged. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
4.5 Spreadsheet calculated midline doses for T1 and T2, along with dose differences between
spreadsheet calculated midline doses and averaged left and right field Monaco determined
midline doses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
5.1 Relative wall scatter (%) for T1 at various different source-chamber and off-axis distances. 54
5.2 Relative wall scatter (%) for T2 at various different source-chamber and off-axis distances. 54
5.3 T1 DD between OOARs calculated from measured data using the PMD and previous
commissioning OOARs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
5.4 T2 DD between OOARs calculated from measured data using the PMD and previous
commissioning OOARs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
5.5 T1 exit-corrected diode measurements of dose (Gy) with TBI setup using the RANDO
phantom, with the left and right fields averaged. ENT and EXIT are abbreviations for
the entrance and exit respectively where the entrance is the closest diode to the beam at
the entrace of RANDO and exit is the diode on the contralateral side. . . . . . . . . . . 64
5.6 T2 exit-corrected measurements of dose (Gy) with TBI setup using the RANDO phantom,
with the left and right fields averaged. ENT and EXIT are abbreviations for the entrance
and exit respectively where the entrance is the closest diode to the beam at the entrace
of RANDO and exit is the diode on the contralateral side. . . . . . . . . . . . . . . . . . 64
6.1 T1 Table of DD between measured and MC modelled OOARs for various OADs and
depths colour coded for specific DD thresholds. Green where DD < 3 %, yellow where
DD < 6 %, red where DD > 6 %. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
xi
6.2 T2 Table of DD between measured and MC modelled OOARs for various OADs and
depths colour coded for specific DD thresholds. Green where DD < 3 %, yellow where
DD < 6 %, red where DD > 6 %. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
6.3 T1 Table of DD between measured and CCC modelled OOARs for various OADs and
depths colour coded for specific DD thresholds. Green where DD < 3 %, yellow where
DD < 6 %, red where DD > 6 %. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
6.4 T2 Table of DD between measured and CCC modelled OOARs for various OADs and
depths colour coded for specific DD thresholds. Green where DD < 3 %, yellow where
DD < 6 %, red where DD > 6 %. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
6.5 DDs between measured diode doses and Monaco modelled doses for similar points in
RANDO, averaged from the left and right fields for both T1 and T2. Green where DD
< 3 %, yellow where DD < 6 %, red where DD > 6 %. . . . . . . . . . . . . . . . . . . . 81
6.6 DDs between interpolated diode and film measurements and spreadsheet calculated mid-
line doses for T1 and T2. Green where DD < 3 %, yellow where DD < 6 %, red where





CCC Collapsed Cone Convolution.
CT Computed Tomography.
DD Percentage Dose Difference.
DOF Diode Orientation Factor.




PDD Percentage Depth Dose.
PMD Phantom Mobility Device.
RGB Red Green Blue Colors.
RO Radiation Oncologist.
SAD Source to Axis Distance.
SCD Source to Chamber Distance.
SPD Source to Point Distance.
SSD Source to Surface Distance.
TBI Total Body Irradiation.




Cancer is a leading cause of death in New Zealand, with 9063 total number of deaths in 2013 (corre-
sponding to 30.7 % total deaths).2,3 There were 22,166 new cases of cancer registered in 2013, with this
number expected to increase over time with an ageing population. Blood cancers are the 4th largest
group of registered cases with 2872 new cases in 2013 (13 % of total registrations).2 Radiation therapy,
also known as radiotherapy is a treatment technique which uses ionising radiation to kill cancer cells
in the body. This technique is highly effective, with over 50 % of cancer patients receiving radiation
therapy treatments.4
Total body irradiation (TBI) is a specialized treatment technique which delivers a radiation dose to
a patient’s whole body. TBI is used to treat patients with Acute and Chronic Lymphoblastic Leukemias
(ALL and CLL), Myeloblastic Leukemias (AML and CML), Non-Hodgkin’s Lymphomas (NHL), and
for bone marrow transplants (BMTs, preventing immunological rejection of the transplanted marrow).
A large surface total (effective) dose (typically between 12 Gy to 15 Gy) is delivered to kill as many
lymphoblastic and myeloblastic cells as possible to suppress or destroy a patients immune system and
malignant cells prior to receiving a bone marrow transplant.5 Modern TBI treatment involves the use
of external beam radiotherapy (EBRT) machines called linear accelerators (linacs), these machines are
capable of delivering targeted radiation therapy treatments with millimeter accuracy and precision to kill
tumorous tissues. To minimize harmful side effects (toxicities) during TBI treatments like interstitial
pneumonitis (IP), treatments are often delivered in smaller doses over two or more sessions (called
fractionations, or fractions of the effective dose).6,7,8 For photon treatments using linacs, a spectrum of
photon energies are produced (polyenergetic beam), therefore the beam is usually described in terms
of its accelerating potential (in MV) which is equal to the peak energy of the spectrum (in MeV).
Through this thesis, where energy is quantified in MV, it refers to the nominal peak energy of the
photon spectrum.
1
Chapter 1. Introduction 2
Context and Motivation
The goal of TBI is to eradicate the patient’s immune system therefore a dose delivered to the whole body
is ideal. The maximum collimator size of most linacs is 40 cm× 40 cm, therefore producing a field-size
large enough to cover the whole of the patient’s body requires some geometrical setup modification to
produce a larger effective field size. There are many methods that have been implemented to produce an
effective field size large enough and with minimal toxicities for useful TBI treatment. These techniques
include Volumetric Modulated Arc Therapy (VMAT),9 sweeping beam,10 translating couch11 and many
others.12 At Christchurch Hospital an extended source to surface distance (eSSD) technique is used to
maximise the radiation field. There are two treatment rooms, a primary treatment room (T2) with an
eSSD of 432.6 cm with beam energy of 15 MV, and a backup treatment room (T1) with an eSSD of
341 cm and beam energy of 10 MV. Bilaterally opposed fields are used with the linac gantry rotated at
a 90◦ angle to produce a horizontal beam, the collimator is rotated at 45◦ to produce a rotated square
field shape which maximises the horizontal field size. Two fields are used by rotating the treatment
couch after each part of a fraction to deliver dose to both lateral sides of the patient. The patient
lies on their back (supine) on a treatment couch between two 2 cm thick beam spoilers with ricebags
packed around the patient to produce a block-phantom like geometry comparable to commissioning
measurements (illustrated later by Fig. 2.8).
Radiation dosimetry enables measurement of absorbed dose to a medium (usually water or water
equivalent material), resulting from exposure to directly or indirectly ionising radiation. When a medium
is exposed to a source of incident ionising radiation, there are several interactions which may occur and
impart energy to the medium including Compton scattering, the photoelectric effect, pair production,
and electronic interactions like bremsstrahlung production. The probability of each type of interaction,
and the energy imparted to the medium are dependent on the initial energy, the type of interaction,
and the tissue composition. Radiation dose interacts with biological tissue causing primarily DNA
strand breaks which results in damage to cells leading to cellular death. It is challenging to measure
the biological effects of radiation accurately in human tissue from a safety and ethics point of view,
therefore water or water equivalent material is often used as it provides a consistent approximation of
human tissue in terms of density. Radiation doses are therefore calculated in terms of their absorbed
dose to water in units of Gray (Gy) where:
1 Gy = 1 J kg−1 (1.1)
Accurate and reproducible radiation dose measurements are essential for the comparison and dis-
cussion about worldwide treatment outcomes in radiation therapy. Primary standard dosimetry labs
(PSDLs) based around the world determine absolute dose values and issue calibration certificates regu-
larly, this provides the link between detectors used for measuring radiation quantities in the hospital to
the primary standard which ensures comparability of absolute dose between different clinics. For stan-
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dard treatments like intensity modulated radiotherapy (IMRT), a ±5 % accuracy of dose is recommended
for optimal patient outcome. However since achieving an even dose distribution in TBI treatment is
difficult difficult to achieve, the established tolerable total dose accuracy is ±10 % for external beam
bilaterally opposed fields as established by the TG-17 report.13,14 There are many different methods of
measuring absorbed dose to a medium, these each have their advantages and limitations and will be
discussed in Sec. 2.1.
1.1.1 Objectives
The work in this thesis has two primary aims. The first is the development of an apparatus to improve
the current methodology in measuring TBI characteristic field data (commissioning data), followed
by an investigation of scattering conditions and using the device in practice. The second focus is to
investigate whether the Monaco treatment planning system (TPS) can be validated and used at eSSD
by comparing with measurement under various conditions.
Before we begin discussing the details of this work it is necessary to frame it within the current
practice at Christchurch Hospital. This section provides a brief discussion on how both the development
of a device to measure radiation dose profiles called the Phantom Mobility Device (PMD), and the
validation of the Monaco TPS were motivated, and how they can be incorporated into the present
clinical setting.
Part of the commissioning process of a linac usually involves the measurement of radiation dose
profiles in a large water phantom which can encompass the full radiation field size for typical isocen-
tric treatments. At eSSD a water tank which would encompass the full field size would need to be
100 cm× 60 cm× 30 cm (length × width × height), which is impractically large. Rather than us-
ing a large water tank, previous commissioning results were measured by physically moving a heavy
28.4 cm× 30 cm× 30 cm standard water tank (used for isocentric measurement) on a sticky TBI couch
positioned using a tape measure. This resulted in a large positional uncertainty of ±2 cm both at depth
and off axis. Additional uncertainties resulting from the time taken to complete all profile measurements,
such as the change in ambient conditions or setup errors further increased the total commissioning un-
certainty. To constrain this uncertainty, the question of whether a PMD which could accurately move
blocks of water equivalent material and a detector to various points off-axis in a timely manner could
be built to improve upon existing measurement methodology.
With common treatments like IMRT or three-dimensional conformal radiotherapy (3D-CRT), the
Monaco treatment planning system (TPS) is used for planning delivered dose to target tumours. For
TBI treatments however, the existing TPS model has not been validated beyond 80 cm to 110 cm
SSDs. Instead, TBI treatment planning currently consists of a spreadsheet calculation based on a
simplified geometric (block-phantom) model of the patient in accordance with AAPM TG-17.13 The
spreadsheet determines the number of MU to prescribe based on the prescribed dose to the midline
(along the midsaggital line of the patient), and the maximum allowable lung dose set by the Radiation
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Oncologist (RO). The spreadsheet takes into account rice bag packing, spoilers and the effective path
length radiation through the lungs based on their respective densities. However since patients bodies
and ricebag packing are both non-uniform, there exists several inhomogeneities which this model does
not take into account. Treatment planning systems utilize the electron densities of tissue determined
from imported computed tomography (CT) scans of a patient to determine dose given to inhomogeneous
structures. It would therefore be ideal if the existing treatment planning model could reliably determine
doses in a patient at eSSD to provide a planning system for TBI. There is therefore a requirement to
characterise the extent of agreement between the TPS model and measured dosimetric results.
The research in this thesis presents novel findings, as whilst there have been many groups publishing
about Monaco treatment planning models15,16,17 and extended SSD TBI models validated using other
TPSs like Pinnacle18,19 and Eclipse20, there have been no published results characterising the Monaco
TPS for clinical use in eSSD TBI conditions.
1.1.2 Thesis Overview
The goals of this research were to improve upon current methodology of measuring commissioning results
in block-phantom geometries, and to determine whether the Monaco TPS could be used for clinical TBI
treatment planning. This project spans a variety of different subject areas including radiation dosimetry
and medical physics, to software and device engineering and mathematical modelling. Necessary con-
cepts will be introduced in a comprehensive manner in order of their significance which will allow for an
understanding of the subject by those without specialist background. Chapter 2 provides an overview of
radiation dosimetry, radiation therapy, treatment planning systems and algorithms with the aim of pro-
viding an understanding of the methodology for measuring dose, and how different treatment planning
algorithms predict dose in a patient. Chapter 3 provides a comprehensive look at the development of a
new device (PMD) for measuring radiation dose profiles in TBI conditions. This chapter will overview
software development and the validation of the PMD with relevant dosimetry equipment. Chapter 4
presents a discussion on the available processes for the prediction of dose in block and anthropomorphic
phantoms within Monaco. Chapter 5 progresses through all linac measurements intended for subse-
quent comparison to Monaco, these allow us to draw conclusions appropriately. Chapter 6 compares
and contrasts TPS modelled results in Chapter 4 with linac measurements in Chapter 5, and discusses
the outcomes of the research in terms of whether Monaco can be used for TBI treatment planning
clinically, and the effectiveness of the PMD for TBI commissioning.
Peer-Reviewed Publication
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Chapter 2
Background
The work in this thesis involves a number of important concepts which span several different areas
of radiation oncology medical physics. It is important to introduce these concepts as they provide a
basis for understanding the methods, results, discussions and conclusions made throughout the thesis.
This section aims to provide an overview of the relevant background starting with an introduction to
dosimetry, from particle interactions to kerma, cavity theory, and how Farmer chamber dosimetry relies
on these concepts. These are followed by an overview of common dosimeters used, concepts used in
modern radiation therapy practice, and finally the local treatment practice of TBI at Christchurch
Hospital is provided.
Dosimetry
Dosimetry is the measurement and determination of the amount of ionizing radiation absorbed by a
material. Absorbed dose (D) is a quantity which describes the energy an ionizing radiation source
imparts to a medium. The absorbed dose to a point is defined as the mean energy dĒ imparted to a
unit mass dm given by Eq. 2.1 below. Absorbed dose has units of Gray (Gy), defined as 1 joule of





A large portion of the work presented involves the measurement of dose. It is therefore vital to
understand the key aspects of dosimetry, the particle interactions which contribute to the total dose,
and the dosimeters used. This section will start with a brief overview of key particle interactions,
followed by how dose to a medium is determined, cavity theory will then be introduced, and finally an
overview of the dosimeters used is given. These aim to provide a clearer picture as to what dose is, how




The experimental work in Ch. 3 and Ch. 5 involves a number of important concepts in radiation
physics as they apply to modern treatment techniques. A few different concepts will be discussed in
terms of particle interactions with absorbing media and their impact on obtained and compared results.
The understanding of these interactions is crucial for their discussion, and to set an appropriate basis
for conclusions of this thesis. Particle interactions in volumes have been covered in-depth by many
standard textbooks,22,23,24,25 the following sections will summarise the necessary theory and results for
discussion points throughout this thesis along with providing the foundation for understanding radiation
dosimetry.
2.1.1.1 Photon Interactions
Photons with energies above 10 eV have sufficient energy to ionise atoms.26 These interactions are
indirectly ionising as, rather than directly producing ion pairs, photons interact with particles and the
coulomb field of an absorber atom and deposit excitation energy, resulting in the emission of particles
and/or photons. Photonic interactions are important not only for understanding how dose is deposited
to a medium, but also for the understanding of scattered radiation. Scatter occurs when a photon
interacts with an absorber atom and an interaction causes the photon to change its direction (and hence
momentum). This direction change results in the photon being scattered at a scattering angle θ best
shown by Fig. 2.1 . This section will provide a brief overview of photon interactions with a medium so




Figure 2.1: Scattering diagram showing a simple example of Rayleigh photon scattering on an atom
(blue) with scattering angle θ.
Rayleigh scattering otherwise known as Coherent scattering occurs when a photon interacts with
orbital electrons of an absorber atom. The photon is scattered at an angle θ with the photon’s energy
change being very small thus the recoil energy of the absorber atom is also small. The atom is not
excited or ionised as a result of this interaction and therefore the angles the photons are scattered
by are small especially for energies where hν > 1 MeV, where ν is the photon frequency and h is
the Planck constant. At lower energies and materials with increasing atomic number (Z) the angular
distribution (commonly known as the Rayleigh characteristic angle, θR representing the half-angle of
a cone which contains 75 % of Rayleigh-scattered photons) of scattered photons increases, however is
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confined to θR(E = 0.1 MeV, Z < 82) ≤ 70◦. The Rayleigh characteristic angle is approximated by Eq.
2.2 expanded from Hubbell.27





Compton scattering occurs when a photon of energy hν interacts with a loosely bound (electron
shell binding energy EB is much less than incident photon energy hν, EB  hν) orbital electron of
an absorber atom. Theoretically it is assumed since the electron is loosely bound that the photon
effectively interacts with a "free and stationary electron". As a result of this interaction two products
are realized: a scattered photon with reduced energy hν′, and a scattered electron also known as a
"recoil" or "Compton" electron having kinetic energy EK . The resulting scattered photon energy can
be described as a function of its scattering angle and incident photon energy described by Eq. 2.3.
hν′ =
hν
1 + hνmec2 (1− cos θ)
(2.3)
For energies above 100 keV, the Compton effect becomes the dominant form of photon interaction.
When high-energy (hν > 10 MeV) photons undergo Compton scattering, most of the incident energy is
given to the recoil electron, as shown in Fig. 2.2. This is important as the work relating to this thesis
involves photon energies in the 1 MeV to 15 MeV range, therefore Compton scattering and its relative
energy transfer is important for us to understand and discuss later on.
Figure 2.2: Graph of the mean energy transferred to recoil electrons, commonly known as "The Compton
graph" showing the mean energy transfer fraction against incident photon energy hν from 1 keV to
100 MeV.
Photoelectric absorption is a process where a photon of energy hν interacts with a tightly bound
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(electron shell binding energy less than but similar to that of the incident photon energy, EB . hν)
electron of an absorber atom.23 The incident photon is completely absorbed, and the electron is ejected
from the atom as a photoelectron with kinetic energy given by Eq. 2.4.
EK = hν − EB (2.4)
Pair production occurs when an incident photon with energy hν exceeds specific threshold energies
when interacting with an absorber atom, the production of an electron-positron pair is possible by
its Coulomb field interaction with either the absorber atom’s nucleus called Nuclear Pair Production
(NPP), or orbital electron commonly called Electronic Pair Production or Triplet Production (TP).
For NPP this threshold energy is hν > 2mec2 and results in an electron-positron pair with the photon
completely absorbed. However for TP the threshold energy is hν > 4mec2, and results in two electrons
and a positron also with the photon completely absorbed. The derivations for the threshold energies
are determined by using the energy-momentum relation as invariant. The produced pair or triplet are
emitted at symmetrical angles.
Photoneutron production occurs when an energetic photon interacts directly with the nucleus of
an absorbing atom causing nuclear disintegration. Nuclear disintegration results in the emission of a
single neutron through a (γ, n) reaction. Since photonuclear reactions are endothermic, there are specific
threshold energies required for specific atomic numbers of an absorber. Therefore linac beam energy
and material of the linac, bunker, shielding, apparatus and patient are all important factors. These
threshold energies are why photoneutrons are only considered for linac energies above 10 MV.
The atomic energy cross section for photonuclear reactions have a broad peak called a giant resonance
extending from their threshold energy, this then diminishes from the peak as energy increases. This
cross section is relatively small compared with competing processes amounting to only a few percent
of the total electronic cross section, even at its giant resonance peak.23 It is therefore usually assumed
negligible in photon attenuation studies. Horikawa et al.28 show that for angles between 90◦ < θ < 270◦
neutron intensity further decreases and therefore backscattered neutrons are less likely than forward
scattered neutrons.
2.1.1.2 Electron Interactions
When a charged particle such as an electron traverses an absorbing medium, Coulomb force interactions
occur between the electron and the absorber’s atoms and their orbital electrons. These interactions
can be split into three different types: soft, hard and bremsstrahlung interactions depending on the
particle’s trajectory, and its distance from the center of the atom (also known as the impact parameter
b) relative to the classical atomic radius a of the absorber atom.
Soft collisions occur when a charged particle traversing the absorber medium has an impact parameter
b much greater than the classical atomic radius a such that b  a. In this case, the charged particle
interacts via Coulomb forces with the entire absorber atom and its orbital electrons. These interactions
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are low in energy transfer (as we know from classical electrodynamics that F ∝ 1r2 with r being the
distance between two charges), however in a conventional medium the number of these interactions is
large and accounts for approximately 50 % of the energy transferred to the absorbing medium. Soft
collisions result in the transfer of energy from the traversing charged particle to the absorber atom, as a
result the absorber atom can be excited to a higher energy state, or ionised by the ejection of an orbital
electron.
Hard collisions occur when a charged particle traversing the absorber atom has an impact parameter b
similar to the classical atomic radius a such that b ≈ a. Hard collisions may result in a significant amount
of energy being transferred by Coulomb interaction between the charged particle and an orbital electron
of an absorber atom. Upon interaction, the orbital electron will be ejected from its atom traversing the
medium as a δ-ray which can also undergo its own Coulomb interactions with the medium. Due to the
narrow range of distances where this interaction would occur, the number of hard collisions a charged
particle would experience is generally small (unlike soft collisions). Since the energy transferred between
the charged particle and orbital electron is large however, approximately 50 % of the energy transferred
to the absorbing medium comes as a result of hard collisions (similar to soft collisions). The maximum





Bremsstrahlung interactions occur when the impact parameter b of the charged particle is much
smaller than the atomic radius a of the absorbing medium such that b  a. When a charged parti-
cle follows this trajectory, it will primarily interact by Coulomb forces with the nucleus of the atom
itself. Most of these interactions are elastic scattering events which only cause a negligible change in
energy and possibly a change in direction. A small number of interactions are inelastic resulting in a
significant energy loss for the charged particle followed by the emission of x-ray photons also known as
Bremsstrahlung photons. This is known as a Bremsstrahlung interaction.
2.1.2 Kerma and Absorbed Dose
The above processes transfer energy to a medium, for the determination of dose, this energy transfer
needs to be quantified. The kinetic energy released per unit mass (kerma) is a quantity defined for
indirectly ionising radiation types (photons and neutrons) as mean energy transferred dĒtr by photons
or neutrons to charged particles per unit mass dm of the absorbing medium. There are two types of
kerma: radiative kerma Krad and collision kerma Kcol both having units of J kg−1. Radiative kerma
is defined where a charged particle produced by a photon interaction (secondary particle) undergoes
a bremsstrahlung interaction and the resulting bremsstrahlung photon has sufficient energy to leave
the medium and thus its energy is not absorbed by the medium. Collision kerma is defined where
secondary charged particles interact by soft or hard collisions where the medium absorbs the energy of
the secondary charged particle (energy transferred from the charged particle to the absorber). The total
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Absorbed Dose Dmed is a similar concept to kerma, however rather than energy transferred it is
defined as the mean energy absorbed dĒab by the medium of mass dm (or energy imparted by ionising
radiation to the medium). Directly ionising radiation types (charged particles) can directly impart
energy to the medium through collision processes previously discussed. However for indirectly ionising
radiation types (photons and neutrons) this is a two part process: firstly energy is transferred to a
secondary charged particle, secondly this charged particle will then traverse the medium and impart its
energy to the medium. Absorbed dose has a special unit called the Gray (Gy) where 1 Gy = 1 J kg−1.
2.1.3 Cavity Theory
Ionisation chambers and their use in measuring dose (dosimetry) are used for a large part of this thesis,
and the principles of their operation are described in Sec. 2.1.4.1. Cavity theory applies directly to
how absorbed dose is determined from measured charge and/or charge rate by an ionisation chamber.
Therefore it is vital to develop the necessary concepts which make up cavity theory, as they apply
directly for the considerations we need to make when measuring dose using ionisation chambers. This
section will introduce the concept of charged particle equilibrium, stopping power, and the Bragg-Gray
and Spencer-Attix cavity theories with the aim of providing an introduction to how dose is determined
using ionisation chambers, and some potential limitations of ionisation chamber dosimetry.
2.1.3.1 Charged Particle Equilibrium and Transient Charged Particle Equilibrium
As previously discussed, when photons travel through an absorbing medium they may interact with the
atoms of the medium through various interactions where secondary charged particles (positrons and
electrons) may be released into the medium. A special case of these secondary charged particles known
as charged particle equilibrium (CPE) can exist under certain conditions. If CPE exists, then the sum
of all secondary charged particles with energies EK which enter a medium of volume V is equal to the
sum of all secondary charged particles which leave the volume V with equal kinetic energies EK . Under
CPE, energy in volume V is balanced in "equilibrium", as the energy lost by secondary electrons which
leave the medium is replenished by the energy of secondary electrons entering the medium. CPE is
shown schematically by Fig. 2.3.
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Figure 2.3: Diagram illustrating CPE in a medium. Monoenergetic photons which are not shown are
irradiating a block of material shown in blue, the white circle within represents a sphere of volume V .
Secondary charged particles produced (black) are shown with their tracks in red, initial and final energy
and the energy where they cross the boundary into or out of V .
The three charged particle tracks shown with respect to CPE existing are;
1. charged particle e0 entering the volume V with energy of 3 MeV and depositing all remaining
energy within V .
2. charged particle e1 produced in volume V and depositing all of its energy within V .
3. charged particle e2 produced in volume V leaving V with energy of 3 MeV.
This demonstrates CPE, as the sum of all charged particles entering V is equal to the sum of charged
particles which leave V and the sum of energy of charged particles entering V is equal to the sum of
energy of charged particles leaving V .
In the case where CPE exists, this means that the dose deposited in V , Dmed is equal to the collision









A more realistic description of charged particle equilibrium for high energy beams (hν > 3 MV) is
the concept of transient charged particle equilibrium (TCPE). TCPE exists for depths z > zmax where
a relationship exists between in-air dose and collision kerma in air and substituting this relationship into
the CPE equality. The transient relationship between dose and collision kerma is given by Eq. 2.8, where
µ is the effective attenuation coefficient of the medium and x̄ is the mean-free path electrons transport
their energy across the medium in the beam direction. The buildup regions exists where TCPE does
not exist in the region where z < zmax. The depth where TCPE is established is energy-dependent. For
energies 10 MV and 15 MV, the depths where TCPE is established are approximately 2.5 cm and 3 cm
respectively.23
2.1.3.2 Stopping Power
The Bragg-Gray and Spencer-Attix cavity theories discussed later in Sec. 2.1.3.3 rely on the concept of
stopping power, it is therefore important to provide a simple conceptual introduction. Stopping power
is a quantity which describes the energy loss of a charged particle per unit path length of an absorbing
medium it travels through. Since interactions between electrons and absorbers can be split into collision
and radiative processes, there are two different respective stopping powers Scol and Srad. Scol decreases
for increasing Z of an absorber whereas Srad increases for increasing Z. The collision stopping power is

























I is the mean ionisation energy.
Z is the atomic number of the absorber.
A is the mass number of the absorber.
z is the atomic number of the charged particle (for electrons and positrons this is 1).
β is the speed of the particle relative to the speed of light, vc .
C/Z is the shell correction factor.
δ is Fermi’s density correction factor.
2.1.3.3 Bragg-Gray and Spencer-Attix Cavity Theories
The determination of absorbed dose in a medium such as a water or a tissue-equivalent phantom involves
placing a radiation dosimeter (cavity) within the phantom. The absorbed dose to the cavity Dcav can
then be measured. Usually the dosimeter cavity is a different medium to the external phantom (for
example, air-cavities within tissue-equivalent phantoms) where absorbed dose to a point Dmed is to
be determined. This difference in medium can lead to the cavity perturbing the photon and charged
particle fluence in the phantom leading to inaccuracies in the measurement of Dmed. The Bragg-Gray
Chapter 2. Background 14
and Spencer-Attix cavity theories deal with the complex relationship between Dmed and Dcav such that
dosimeters can be used accurately for the measurement of dose within other mediums. This section will
discuss the Bragg-Gray and Spencer-Attix conditions and what these mean for radiation dosimetry in
cavity dosimeters.
For a cavity to be classified as a Bragg-Gray cavity for photons with an energy hν > 200keV , two
conditions must be met which are as follows:
1. The size of the cavity, d must be much smaller than the range of secondary charged particles, R
which cross it (d R). This condition avoids the cavity perturbing the secondary charged particle
fluence produced by photon interactions within the medium so that the secondary charged particle
fluence of the cavity is approximately equal to that of the medium (ϕcav ≈ ϕmed). small cavities
also provide better spatial resolution of measurements.
2. The absorbed dose in the cavity, Dcav is deposited solely by secondary charged particles crossing
the cavity. Photon interactions are ignored as they are rare and therefore negligible.













The Spencer-Attix cavity theory extends the Bragg-Gray theory for small cavities by establishing
an energy threshold for secondary charged particles in the medium. This threshold energy means that
secondary charged particles which have enough energy to produce bremsstrahlung photons which can
carry energy outside of the cavity are excluded. To do this, a mean restricted mass collision stopping
power ( L̄∆ρ ) with kinetic energy threshold ∆ of 10 keV replaces the unrestricted mass collision stopping
power ( S̄ρ ) in Eq. 2.10.
The Bragg-Gray cavity theory establishes a well understood method for which absolute dose can be
determined in a small air cavity which is representative of a dose in the medium it is placed within.
The Spencer-Attix extension of the Bragg-Gray theory to exclude higher energy electrons increases the
accuracy of the determination of dose significantly therefore allowing for the appropriate determination
of absolute dose in modern ionisation chambers.
2.1.4 Dosimeters
Three different dosimeters are used in Ch. 5 for the measurement of dose in block-phantoms and
anthropomorphic phantoms. This section will provide an overview of the dosimeters used, starting with
Farmer-type ionisation chambers, followed by radiochromic film, and ending with diodes. The goal is
to provide an understanding of how these dosimeters work, how they are used, and their drawbacks.
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2.1.4.1 Farmer-type Ionisation Chambers
Farmer chambers are a type of thimble ionisation chamber, that consist of a cylindrical thimble-shaped
wall and a cavity with typically 0.6 cm3 air volume. A central and outer electrode with a polarizing
voltage applied to the outer electrode with the central electrode grounded, generates an electric field
between the two electrodes. As secondary electrons produced in a larger external volume cross the
sensitive volume of ambient air inside the chamber they ionise it causing electrons and positions to be
produced, which are separated by the electric field across the electrodes. Depending on the polarity of
the voltage applied, a positive or negative charge will then be recorded by an electrometer over time.
There are several advantages and disadvantages of Farmer chambers. Advantages include: High
accuracy and precision, simplicity of measurement and reproducibility, flat energy response over a wide
range of energies, negligible directional dependence, instant readout, able to determine absolute dose,
correction factors and cavity physics well understood. Disadvantages include: spatial resolution limited
by collection volume, leakage currents from the chamber, electrometer and cable, non-water equivalent
chamber materials and medium so many correction factors need to be applied, high voltage supply
required.
Figure 2.4: Schematic diagram of farmer chamber operation. (a) Shows the air cavity within a larger
volume VL which could be any measurement medium. (b) Represents the cross section of the cylindrical
Farmer chamber with central and outer electrodes in blue. (c) Illustrates the entire farmer chamber.
(Reproduced from Podgorsak EB. Radiation Physics for Medical Physicists. Springer Publishing, 2016,
with permission)
Fig. 2.4 illustrates schematically the internal components of a farmer chamber in a medium of
volume VL. The volume VL may be air, water, or any other type of medium the chamber measures
a dose within. We have previously discussed the Bragg-Gray and Spencer-Attix cavity theories and
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how they consider the perturbation of electron and photon fluence by the cavity within the medium.
An expression for absorbed dose to the medium based on the charge measured by a farmer chamber is


























mass stopping power ratio of the medium of volume VL to the air in the cavity.
The concept of TCPE is important for the accuracy of farmer chamber dosimetry as the measure of
charge or charge rate from secondary charged particles ionising air depends on the energy and fluence
equilibrium of charged particles in the cavity. As previously mentioned when TCPE does not exist,
the relationship between collision kerma and absorbed dose does not hold and therefore the measured
charge or charge rate for depth z < zmax would not be representative of dose.
In clinical practice, quantities such as stopping power ratio and mean energy required to produce an
ion pair are not measured, instead a secondary standards dosimetry lab (SSDL) which have equipment
calibrated to a PSDL, perform calibrations for and provide calibration coefficients for a given chamber in
clinical use. These calibration coefficients include the absorbed dose per nano coulomb to water ND,w,Q,
and the radiation quality coefficient kQ,Q0 which corrects for the differences in SSDL and treatment
centre beam qualities. There are a few other centre-measured factors such as kpol the response of an ion
chamber with respect to its polarizing voltage, kTP corrects for the chamber response based on changes
in ambient pressure and temperature, ks corrects for lack of total charge collection due to recombination
of produced ion pairs. These correction factors fit in with IAEA’s TRS-398 ND,w formalism31 for the
determination of absorbed dose to water in high-energy photon and electron beams using an ionisation
chamber. Calculating absorbed dose to water using this formalism is done using Eq. 2.12.
Dw = ND,w,Q0 ×MQ × kQ,Q0 × kTP × ks × kpol (2.12)
Where MQ is the charge measured by an electrometer and Dw is the absorbed dose to water.
Of note is the interchangeability of charge and dose to charge rate and dose rate, as if we substitute
charge for charge rate, ṀQ then the calculated quantity is absorbed dose rate to water Ḋw. Additionally,
the derivation of ∆kTP from kTP is given by Eq. 2.13, this is important for later discussion of small







− P0 × T ×∆P
T0 × P 2
(2.13)
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2.1.4.2 Radiochromic Film
Radiochromic film dosimetry is a type of chemical dosimetry based on the change in colour of radiation
sensitive film when exposed to ionising radiation. Dose is inferred from the film’s colour change. The film
develops in real time with no post-exposure treatment required. To determine dose the film is scanned on
a flatbed scanner where the amount of light which is transmitted through the film is directly related to
the dose of ionising radiation absorbed by the film, and by the scanning light’s wavelength. For absolute
dosimetry measurement, a set of calibration film is typically required along with an absolute measure
of dose to the calibration point to generate a calibration curve for which the relationship between dose
and the three colour channels (red, green and blue) can be established. Once this relationship has been
established this can be used to determine the absorbed dose for a measurement.
The advantages of radiochromic film are that they are near tissue equivalent (effective Z between 6.0
and 6.5 compared with approximately 7.42 for water32 which is a reasonable approximate for human
tissue in its entirety), have a high spatial resolution, large dynamic range, relatively low energy depen-
dence in the MV range, insensitive to ambient conditions during measurement and allows for 2D dose
mapping. Disadvantages include: non-instant readout, determination of absolute dose requires careful
calibration, reproducibility difficult to achieve between differing film batches. Several studies evaluate
the Gafchromic EBT-3 radiochromic film used in this thesis33,34,35 in terms of the compositions, lat-
eral response artifacts, sensitivities, resolution and energy-dependence over a range of doses for photon
beams.
2.1.4.3 Diode Detectors
Silicon diode detectors are a common choice used for relative dosimetry due to their higher sensitivity,
instantaneous output and small size compared with ionisation chambers. Their major limitations include
energy dependence in photon beams, directional dependence, thermal effects and radiation-induced loss
of sensitivity over time. Modern diodes used in dosimetry have been made to reduce negative effects and
are well suited for relative measurements, output constancy checks and in-vivo patient dose monitoring.
Diodes are currently often used for in-vivo patient dose monitoring during TBI treatments.
Radiation Therapy Quantities in Practice
Given a linac beam incident on a patient or phantom, the absorbed dose varies dependent on a number
of factors. This variation includes beam energy, depth, field size, distance from the source, beam
collimators, scatter and changes in ambient conditions. The determination of dose in a patient requires
considerations and understanding with respect to these parameters and impacts. It is therefore essential
to establish the variation of dose along the central axis and off-axis of the beam at varying depths in a
patient or phantom. A number of quantities have been defined for this purpose which will be explored
in this section, along with other quantities and terms in radiation therapy used through this thesis.
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Monitor Units are a measure of beam output from a linac as measured by an ionisation chamber
within the linac head called a monitor unit chamber. linacs are calibrated such that their nominal
output at 100 cm SAD at 10 cm depth in water is 1 cGy MU−1. This means for every monitor unit
delivered, 1 cGy of dose is delivered to a point 10 cm deep in water at 100 cm SAD.
Dose profiles are a measure of dose at a perpendicular plane transverse to the radiation beam direction.
Profiles provide an understanding of the variation of dose as a measurement point moves away from
the beam’s center (central axis shown schematically in Fig. 2.5), or off-axis. Since linacs produce a 3D
dose which can be visualised as a 2D dose profile there are two primary profile directions: inline where
off-axis deviations are inline with the gantry and crossline with off-axis deviations perpendicular to the
gantry.
Percentage depth doses (PDDs) quantify how dose varies with depth in a phantom and distance from
a radiation source. The PDD is determined by measuring doses at varying depths within a phantom
with a fixed source to surface distance (SSD). For a given phantom and linac setup, determined PDDs







Figure 2.5: Setup for measuring a PDD showing schematically the SSD, depth z and doses Dz, Dmax
in a water phantom.
Tissue phantom ratios (TPRs) quantify how depth within a phantom affects the dose to a point for
a fixed source to axis distance (SAD) best illustrated by Fig. 2.6. The TPR is acquired by measuring
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doses at a reference depth and alternative depths whilst keeping the SAD fixed. Doses at the alternative



















Figure 2.6: Tissue phantom ratio diagram showing schematically the SSD, SAD, depth z and doses Dz,
Dref in a water phantom. This illustrates that for SAD to remain fixed that the SSD must change when
determining the TPR at each depth.
Off-Axis Ratios (OARs) relate the ratio of the dose for a given depth at distances away from CAX
given by Eq. 2.15. The OAR is dependent on the field size, beam energy, depth and off-axis distance.
The plot of off-axis factors for a given depth including the CAX point is known as the beam profile.




Where Dz,x is the dose at depth z and off-axis distance x, and Dz,x=0 dose at depth z at CAX.
Output Off-Axis Ratios (OOARs) are a similar concept to the OAR, however rather than normalizing
doses off-axis to the CAX point for each depth, the doses are normalized to the point where output is
determined. Output is typically determined at CAX and at a depth of 10 cm in a water or solidwater
phantom. OOAR is determined using Eq. 2.16 and much like OAR depends on depth, field size, beam
energy and off-axis distance.
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Where Dz,x is the dose at depth z and off-axis distance x, and Dzo,x=0 dose at output depth zo at CAX.
The OOAR is clinically useful concept when calculated from measured data, as it provides a lookup
table where dose can be determined directly from the table, and is proportional to the number of MU
delivered (subject to treatment correction factors). The OOAR is essentially a dose profile of all TPRs
at the output point. The plot of OOARs vs off-axis distance or depth is still a dose profile or TPR
(respectively), they have however a different point of normalization (which is more clinically relevant).
Percentage Dose Differences (DDs) are a quantity defined for the comparison between two or more
doses and their agreement with one another.
DD(%) = 100× D1 −D2
MAX(D1, D2)
(2.17)
Where D1 and D2 are doses at two different spatial points in a radiation field. These doses can
be absolute, relative, or normalized doses with the dose difference reflecting the difference between the
quantities at different points relative to their maximum.
The clinically useful field size or dosimetrically useful field size is defined as an effective field size
which achieves a 95 % isodose coverage of the phantom or patient, for TBI purposes. This means that
the whole patient is covered by 95 % of the total dose.
Treatment Planning Algorithms and Systems
Treatment planning in radiation therapy represents a major part of the overall treatment process. TPSs
are used to generate beam shapes and dose distributions to maximize dose delivered to a tumour and
minimize dose to healthy normal tissue. There are a number of different approaches modern TPSs
use for determining dose within the patient, several algorithms and methods have been developed
for the calculation of dose each with their own advantages and drawbacks. These algorithms and
methods include Monte-Carlo (MC), Collapsed Cone Convolution (CCC), Pencil Beam Convolution
(PBC), Analytical Anisotropic Algorithm (AAA) to name a few. The Monaco TPS used through this
thesis uses two primary algorithms: CCC and MC. This section will discuss the MC and CCC algorithms
generally, and then conclude by comparing the algorithms as they are implemented in Monaco.
2.3.1 Monte Carlo Simulation
Monte Carlo simulation (MC) is an important concept in RT treatment planning. The MC method is a
broad methodology of simulation using defined randomness as input such that it is possible to emulate
a real system with many coupled degrees of freedom or where inherent randomness exists. In an MC
dose calculation, tracks of each ionising particle passing through a medium are simulated.36 Particle
interactions with the medium are simulated along the track using a random number generator and the
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probability distribution of the different interaction types that may occur given the particle’s energy.
Interactions are simulated along the track until the particle has lost all of its energy via interactions
with the medium. For the calculation of dose to a given volume of interest (VOI) the algorithm just
needs to determine the change in energy for particles traversing the VOI divided by its total mass. For
the simulation of dose deposition many primary particles and their associated secondaries are tracked
until all the energy is either absorbed or leaves the simulated world. Accuracy of results is improved by
increasing the number of simulated primaries (commonly referred to as histories).
2.3.2 Collapsed Cone Convolution Algorithm
Collapsed Cone Convolution (CCC) algorithms were developed to provide a faster means of determining
expected dose to VOIs whilst maintaining a suitable (≤ 2 %)37 difference from the true dose. The CCC
algorithm works in three primary steps: Photons are first ray traced through the medium (consisting
of volumetric segments called voxels). As photons interact with the medium, energy is transferred to
the medium and its voxels, collectively called the total energy released per unit mass (TERMA).38
Secondly the interactions in the voxels produce secondary electrons which traverse in all directions and
transfer their energies to nearby voxels. The energies transferred to voxels from an interaction point
is accumulated into a kernel (which is typically pre-calculated with MC simulations). Finally the total
dose deposited in the medium can be determined via the convolution of the TERMA distribution with
the kernel.
2.3.3 Monaco Treatment Planning System
Monaco is a treatment planning system developed by Elekta (Elekta AB, Stockholm, Sweden) which
incorporates PBC, CCC, and MC algorithms for calculation of dose to VOIs. Christchurch Hospital
primarily uses CCC and MC in treatment planning practice, and it has been shown in other TPSs that,
for eSSD TBI and for lung dose calculations, PBC performs significantly worse than CCC and MC
algorithms.19,37 Therefore it was deemed for this thesis that only the existing CCC and MC algorithms
(validated up to 110 cm SSD), would be evaluated.
Monaco uses VMC++ for its MC calculation of dose. VMC++ is a unique implementation whereby
particles of the same energy but different position are bundled into sets called particle sets. A simple
transport equation is formulated based on stopping power and the continuous slowing down approxima-
tion of charged particles, whereby a particle transport equation of interactions with the medium can be
formulated in terms of energy rather than path length. This, with the combination of electron track his-
tory repetition from homogeneous media, means that VMC++ proves to be significantly more efficient
than a standard MC simulation.39 The model, whilst more efficient, does take several aforementioned
shortcuts which may make it unusable at eSSD.
CCC calculation of dose in Monaco is performed using the technique discussed in Sec. 2.3.2. Since
pre-calculated kernels are used, if these do not extend beyond 110 cm SSD this may cause errors in the
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calculation of dose. An advantage of CCC however is the use of ray tracing. Since photons are ray
traced through media, this may enable CCC to accurately compute interaction points at eSSD.
It is unclear which algorithm will perform the best at eSSD. One of the central aims of this thesis is
to evaluate both algorithms at eSSD in a homogeneous phantom.
Local Treatment Practice of TBI
This section covers the local practice of TBI, starting with common equipment used, followed by in-
troducing current TBI treatment planning, then discussing how patients are setup for treatment and
finally discussing in-vivo dosimetry used for checking doses during treatment.
2.4.1 Common Equipment Used
There are several key items of equipment used for measurement of dosimetric quantities in this thesis.
This section provides a quick reference to these pieces of equipment, along with shorthand names used
through the thesis for them.
• Solid Water HE commonly referred to as "blue solid water", Original Solid Water commonly
referred to as "brown solid water" both produced by Sun Nuclear Corporation.40,41
• 0.6cc NE2571A farmer chamber (Phoenix Dosimetry Ltd.)42
• PTW UNIDOS E T10009 Electrometer.43
• PTW T41023 water tank.44
• Two linacs are used, an Elekta Synergy (in treatment room 1) and an Elekta Versa HD (in
treatment room 2).45,46
• RANDO Alderson (Radiology Support Devices Inc.1) Anthropomorphic phantom.
2.4.2 Treatment Planning
TBI Treatment planning currently consists of a spreadsheet calculation using a simplified geometric
model using commissioned profiles and TPRs. The spreadsheet calculates dose along the patient midline
along with the maximum lung dose. As mentioned these calculations are based on a simplified model
and do not take into account things like inhomogeneities, full tissue scatter conditions, and variations
in organ sizes and positions.
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Figure 2.7: Schematic of the TBI calculation spreadsheet showing patient dimensions measured prior
to treatment.
Patient dimensions are physically measured prior to treatment and values are entered into the spread-
sheet, best illustrated by Fig. 2.7. The allowed lung maximum dose and prescribed midline dose are
entered along with patient-specific information. Expected midline doses are then determined along with
the number of monitor units to use for field and the perspex side panel separation. This information is
then saved and used during patient setup.
2.4.3 Patient Setup
The current TBI treatment technique at Christchurch Hospital involves opposed bilateral fields to a
patient lying supine at eSSD. The gantry is rotated at 90◦ and collimators angled at 45◦ such that the
long-axis of the patient is in line with the diagonal of the field this is best shown by Fig. 2.8. Two
treatment configurations are currently used;
1. Treatment room T1 (T1) with 10 MV photon energy and SMD of 341.0 cm with dosimetrically
useful field size of 120 cm.
2. Treatment room T2 (T2) with 15 MV photon energy and SMD of 432.6 cm with dosimetrically
useful field size of 170 cm.
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Figure 2.8: Schematic of TBI patient setup viewed from the beam’s eye view. The yellow represents
the diamond-shaped radiation field defined by the collimator at a 45◦ angle. Dashed lines represent the
beams axis and cross over at the groin midline prescription point. The black solid rectangle outline
around the patient represents the beam spoilers with ricebags packed within to make a uniform 3D
rectangular volume.
Patients treated on T1 have to bend their legs at the knees, Patients treated in T2 can usually lie
flat (unless they are taller than 170 cm). The midline CAX dose rate is in the range of 5 cGy/min to
15 cGy/min. Rice bags packed around the patient are used as a dose distribution modifier (bolus) to
minimize the variation in midline doses due to changes in patient lateral separation. From previous
measurements, the rice bags were found to have the following attenuation factors:
1. T1 (10 MV x-rays): 0.891
2. T2 (15 MV x-rays): 0.880
Two 2 cm thick perspex side panels cover the length of the patient and act as beam spoilers in order
to increase the electron fluence hence removing skin sparing effect of the high energy beams. These
spoilers have attenuation factors of:
1. T1 (10 MV x-rays): 0.993
2. T2 (15 MV x-rays): 0.992
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2.4.4 In-vivo Dosimetry
In-vivo dosimetry involves using dosimeters to measure radiation dose to the patient during treatment.
During TBI treatments, diode dosimeters (discussed in Sec. 2.1.4.3) and a farmer chamber are used for
in-vivo dose verification. Diodes are placed at key locations on the entrance and exit to the head, neck,
chest, umbilicus, mid-thighs, mid-calves and ankles and the farmer chamber is placed in the groin with
a single groin diode taped to the thigh closest to the beam. Diodes are calibrated yearly to be within a
2 % tolerance with respect to dose measured.
Diode and farmer chamber measurements are compared with spreadsheet calculations for validation
that predicted midline doses are within ±10 % of the measured midline doses (determined by interpo-
lating measured diode results), and the farmer chamber prescription point dose.
Chapter 3
Phantom, Phantom Mobility Device,
and Dosimetry
This chapter discusses the development of the Phantom Mobility Device (PMD) and validation of
equipment used for measuring dose. Firstly we will outline the purpose of the development of the PMD,
followed by the design and considerations. Software development will then be discussed, followed by the
validation of dosimetric equipment and the PMD. Finally a brief section about the implementation of
the PMD into the clinic will be given providing a reference to the produced protocol document.
Purpose
We have previously introduced that localization uncertainties during the TBI commissioning measure-
ments of profiles and TPRs in a block phantom were relatively large (±2 cm). To reduce this uncertainty
in the measurement point, a device which would move a water tank, or blocks of solid water, along with
a detector, was devised. This section discusses the design, validation and implementation of the PMD
and dosimetry related to its automation.
Design
A device was developed using a belt-drive system for movement of blocks of solid water material. Previ-
ously a worm-drive design was considered for movement of the phantom, but considering an estimated
weight of 60 kg (excluding the tray) and the total length of the drive (2 m), there was concern about pos-
sible flexing in the centre causing additional localization uncertainty and instability over a long period.





Figure 3.1: Image of the final PMD design (a) shows a full complete view of the PMD and control box
(white). (b) Demonstrates the PMD in-use, filled with solid water.
Fig. 3.1 shows the final design featuring a belt-fed track system with a wooden tray supporting
blocks of solid water, this sits on a large frame which fits atop of the treatment couch. The inner
free area of this tray was 600 mm× 300 mm such that solid water can fit onto the tray and can be
stacked in all 3 directions. The belt mechanism was driven by a stepper motor with resolution of
0.015 mm/step, controlled using an RS232 interface, allowing for the automation of measurements since
both the movement and electrometer read-out are interfaced digitally over RS232. The entire assembly
is an overlay sitting on-top of the bare treatment couch, thus the corner of the overlay could be kept at
the same corner of the couch, thus allowing for repeat measurements over multiple days/weeks without
sacrificing measurement-point localization accuracy.
The PMD was built by Geoffrey (Geoff) Graham at the University of Canterbury physics workshop.
Final design was decided on after discussions of material type, the mechanisms used and their sustain-
ability in an environment subjected to ionising radiation, and the design in terms of how it would be
applied and used to constrain measurement uncertainty as much as possible.
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Software Development
A program written primarily in C# named TBIControl was developed to interface with the PMD
and electrometer over RS232. TBIControl made the process of measuring profiles and TPRs semi-
autonomous. This section covers a few key points of what was included in the software as this is
important for the reproducibility of results in this thesis. The code and compiled binary is linked in
Appendix D.
3.3.1 Main Menu
The main menu of TBIControl is focused on connecting the necessary equipment via RS232 and validat-
ing the equipment is connected. RS232 is connected to by selecting the relavent port in the dropdown
menu beneath the respective PMD and electrometer and pressing the "connect" button. Once connected
a handshake output may be received (if configured in the options for the handshake command), this
handshake may be a serial number of the device or something similar (user-configurable) and will output
to the read-only text box beneath the connection options. To disconnect simply "close" the connection
via the red button next to the connect, this will free up the COM port. Fig. 3.2 illustrates these menu
options.
Figure 3.2: Image of TBIControl’s main menu showing PMD and electrometer RS232 drop down,
connection options and handshake output.
At the upper left and right within all pages, there is a method menu (top left) and an options menu
(top right). The method menu contains the range of functions which can be used with the PMD and
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electrometer, and the options menu contains configurable settings and a way of exiting the program.
The bottom right of the program contains a coloured circle with the status of the program, it is red
when busy and green when idle.
3.3.2 Settings
Due to the wide range of possible configurations for other PMDs and electrometers, and due to time
constraints involved with this thesis, it was determined that a completely user-configurable settings menu
should be created. This allows end users to configure TBIControl for their own devices by researching
the documentation provided by their product manufacturers and entering the relevant information in
the settings. Some information may be more trivial than others to obtain, the base commands for
example should be in the default documentation of most manufacturers electrometers, and should be
known to those who build a PMD. Commands such as the data index however may be a little more
difficult to find, PTW had extensive documentation where they provided sample output of commands
where the data index was readily determinable, however this will vary between manufacturers.
Figure 3.3: Image of TBIControl’s user-configurable settings within the options menu.
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Fig. 3.3 shows the various user-configurable settings for both the electrometer and PMD. Most
settings have informative tool tips about what they are and where this information can be found for
different devices. Once saved these settings are persistent for the program and are saved under "%Ap-
pData%/Local/TBIControl".
3.3.3 Move PMD
The Move PMD interface was developed for full control over the PMD. The speed and position of the
PMD tray were configurable, along with being able to initialize the PMD to prepare it for use. The
move mode could also be changed so that the tray could be moved to absolute discrete locations or
in relative steps from its current location, it could also be sent out to its maximum extents in both
directions.
Figure 3.4: Image of TBIControl’s Move PMD method.
The Move PMD interface is best illustrated by Fig. 3.4, where all user editable settings are shown.
3.3.4 Electrometer Read
Electrometer read was designed to read out charge rates from the electrometer over a set period of
time. These charge rates were all output as text in comma separated values format in the "Charge Rate
Output" text box. Once measurement had completed, the arithmetic mean, standard deviation, and
standard error of the mean were all computed and provided in the respected text boxes shown in Fig.
3.5.
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Figure 3.5: Image of TBIControl’s Electrometer Read method.
The purpose of electrometer read was to test reading out the electrometer over long periods of time
to ensure stability, and for measurement of charge rates at specific points over time which were useful
in following sections.
3.3.5 Step and Record
Step and record mode was designed to semi-autonomously acquire profiles over a range of depths with
an electrometer and PMD connected via RS232. A user would enter input parameters for measurement
as shown by Fig. 3.6. Once entered and started with the solid water and chamber in position at the
first depth, the PMD would record a profile step-wise. Multiple charge rates are recorded for each
point off axis whenever either the electrometer buffer updated or 0.5 s elapsed since last measurement
(whichever happened first). Charge rates are averaged, providing the mean charge rate, standard
deviation, and experimental standard deviation (uncertainty of the mean) determined using methods
discussed in Appendix B. Once the profile acquisition is complete for a given depth, it will ask whether
the recording was "successful", selecting "no" will cause a repeat of this profile measurement. This was
useful for preventing linac termination faults requiring segments of data to be remeasured after the set
was complete. Finally at the end of all profile measurements over all depths the data is saved under
"SRsave-DDMMYYYYHHMMSS" format. This data can be plotted on the spot using the plotting
controls, or exported to a spreadsheet for external analysis.
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Figure 3.6: Image of TBIControl’s Step and Record method.
Fig. 3.6 shows step and record mode with two sets of real data acquired, saved and plotted using
the plotting controls.
Equipment Validation
Once the PMD had been built, it was necessary to validate the necessary dosimetry equipment along
with the PMD itself so that any limitations of equipment used could be quantified. This was important
for measurement using the PMD, and for the software design of TBIControl’s methods as it allowed for
appropriate use of the PMD when making dose profile measurements.
3.4.1 Electrometer
Quantifying the temporal resolution of the PTW Electrometer over RS232 was important, since we
would be using it with the PMD for measurement of charge and charge rate. To quantify this, the
electrometer’s bias voltage was set to 0 V, and a 3 Vpp, 3.3 Hz signal was applied via a BNC to TNC
connector from a Signal generator to our electrometer. This allowed the determination of the temporal
resolution of our electrometer by continually reading out the charge and current via the RS232 interface
with python at the highest possible baudrate (19200).
33 3.4. Equipment Validation
(a) (b)
Figure 3.7: Temporal resolutions of both measured (a) charge and (b) current, using a signal generator
and PTW Electrometer.
Fig. 3.7 shows that the temporal resolution of the electrometer when read-out is in-fact limited
to 0.5 s (which is the update-time on the electrometer’s display), this is demonstrated as even though
there is a changing current/charge faster than the 0.5 s display update (3.3 Hz Square wave from signal
generator), the multiple data points at each output have the exact same data value in the interval of t0
and t0 + 0.5 s.
3.4.2 PMD Speed and Positioning
The speed and positioning accuracy of the PMD were required to be validated immediately after it
was built. Since the device was intended to measure profiles and TPRs, the speed and position were
important quantities to measure such that the off-axis positional uncertainty of the farmer chamber
could be realized.
A python script was created to characterise PMD motion in terms of speed by having the PMD
traverse a set distance and recording the time it took to reach that point. The script would also sample
the change in distance over smaller time steps to record a set of speeds. These speeds were analysed and
initially it was found that as the speed increased, the actual speed became increasingly less than the
reported speed. This data was collected and provided to Geoff and he was able to make the appropriate
adjustments to the assembly code on the micro-controller such that the speed was then equal to the
reported speed for all speeds tested.
Positioning accuracy was tested vigorously by moving the PMD to set points across the entire 1.8m
track and verifying the position via measurement with a ruler with 1 mm divisions. Due to the limitations
of time and the measurement device used, the PMD was only verified to a ±1 mm position accuracy.
These limitations could be overcome by using a vernier caliper for sub-millimeter precision.
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Figure 3.8: PMD speed and positioning validation using a python script on a laptop (left) connected
by RS232 to the PMD (right).
Validation setup of the PMD is shown in Fig. 3.8. Along with testing the positioning accuracy,
positioning of the PMD over time was also tested. This was done using a python script to test the PMD
in position step mode and continuously back and forth. Positions were again tested using a ruler for the
PMD step mode and were validated to a ±1 mm position accuracy over a 4 h continuous run time. For
continuous mode, an audio sound was set up to play from the testing laptop at specific positions, this
was then compared with a ruler placed at these positions. At high speeds continuous mode was very
difficult to measure with high accuracy therefore for speeds v > 10 mm/s the positional accuracy could
only be validated to ±2 mm whereas for speeds v < 10 mm/s the positional accuracy could be validated
to ± 1 mm. The measurement of continuous movement positioning could have been improved with the
use of a laser at each validation point.
3.4.3 PMD Scatter Contribution
The PMD contained a number of metal components and additional material over the base TBI couch.
In Sec. 2.1 we discussed different types of scatter and its contribution to dose. Therefore it was
important to determine whether the additional material the PMD introduced would contribute any
measurable scatter to the measurement point. If the scatter was measurably significant it could perturb
measurements made using the device, therefore directly affecting results.
To evaluate this, charge rate was measured for various points along the PMD with a farmer cham-
ber with a buildup cap (wall thicknesses of 2 mm 2.5 mm for energies 10 MV and 15 MV respectively)
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suspended in-air using a retort stand. For each point along the PMD the couch was moved such that
the chamber was kept at CAX such that measurements were directly comparable with no off-axis con-
siderations required. A measurement was also taken on the base couch without the PMD such that the
scatter could be characterised as a proportion of the primary beam output. Measurements were taken
using TBIControl’s electrometer read (Sec. 3.3.4) with 10 s of record time per step.
(a) (b)
Figure 3.9: Normalized PMD scatter in (a) T1 treatment room and (b) T2 treatment room. In-air
charge rate measured at various positions along the PMD normalized to the in-air charge rate on the
bare couch without the PMD.
Fig. 3.9 shows our PMD scatter for various points along the PMD (red) with reference to an
ideal case with no scatter (blue). All measurements in both T1 and T2 fluctuate about the ideal
case given their uncertainty (95 % confidence interval) evaluated according to Appendix B. Intended
measurements conducted with the PMD would use solid water, with the detector in all but one direction
(the direction with the least amount of PMD material) being surrounded by ≈ 12 cm of attenuating
solid water material. Given the scatter factors combined with uncertainties, along with the intention of
use, it is reasonable to conclude that the PMD would contribute no measurable amount of scatter to
measurements, given the uncertainties.
Implementation
Over the course of using the PMD several times for profile and TPR measurement, an optimal best prac-
tices document was created for implementation of the PMD for future measurements. The motivation
behind the document was to promote consistency and understanding in measurement whilst allowing
measurements to be performed as efficiently as possible. The document is now appended to the TBI
protocol document, and is provided in Appendix A.
Chapter 4
Treatment Planning System Modelling
at eSSD
This chapter discusses modelling of eSSD TBI dosimetry and treatment using Monaco and the existing
spreadsheet described in Sec. 2.4.2. Firstly a block phantom was contoured in Monaco with modelled
results acquired to determine whether the difference of agreement between modelled and measured
results was clinically acceptable given measurement and model uncertainties (DD < 6 %). Once this
was determined, anthropomorphic measurements were justified, so the RANDO (Alderson RANDO
phantom, Radiology Support Devices Inc.1) phantom CT was used to model point doses for comparison
to measured point doses. The modelled block phantom and anthropomorphic measurement sets along
with spreadsheet determined midline and peak lung doses provide the basis for comparison to the
measured sets to determine the possibility of clinical implementation. This chapter provides methods
and results of phantoms modelled in Monaco along with the existing spreadsheet determined results
of midline doses using the RANDO phantom. Firstly we will look at our block-phantom Monaco
modelled results, followed by anthropomophic phantom Monaco results, finally we will provide the
existing spreadsheet midline and peak lung doses given the RANDO phantom geometry and compare
these with Monaco modelled midline and peak lung doses. This chapter sets up the basis for comparison
of results in Ch. 6, along with providing a quantitative assessment of the existing spreadsheet relative
to the Monaco model.
Block Phantom
Determination of profiles and TPRs in a block phantom using both the MC and CCC algorithms were
initially undertaken to validate the feasibility of using Monaco for eSSD treatment planning. Results
from each algorithm were compared with each other along with the determined uncertainties produced
by Monaco. The intended end result was to compare these results with measured beam profiles and
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TPRs in a block phantom composed of a combination of solid water and water to determine the difference
of agreement between measured and modelled results, which is discussed in chapter 6.
4.1.1 Methods
In order to compare Monaco beam profiles and TPRs at various depths in a water phantom to those
measured during commissioning and with the PMD, the following steps and procedures were undertaken.
1. Monaco required an external volume to prevent it from crashing and so that the dose algorithms
would not have issues with isocentre "being outside a treatment/patient volume". Therefore
producing a phantom using Elekta’s DICOM creation tool CarpeDicom (Elekta AB, Stock-
holm, Sweden) with 1 cm divisions (smaller divisions caused Monaco to crash) of dimension
500 cm× 220 cm× 50 cm was done to fulfil this requirement.
2. Creating one external volume of smallest relative electron density to water (minimum allowed
was 0.01) of dimension (SMD− 100 cm)× 220 cm× 1 cm [x, y, z] which encapsulated our internal
structure(s), this slice was placed at the edge of the empty phantom so as to be within the phantom
but as far away as possible from the internal structures (at position y = 109.5 cm) and the beam.
This external volume is best illustrated by Fig. 4.1.
3. Added an interest point which the beam could use as isocentre, close to the edge of the external
volume, this interest point would vary in x and y positions in order to adjust for off-axis distances
and TPR depths (such that the beam moved closer at deeper depths to maintain 432.6 cm source
to point distance (SPD) for a point at the measurement depth).
4. Creating the water phantom, due to the 1 cm divisions in Carpedicom the phantom had to be
created between z = 15.5 cm and z = −14.5 cm, therefore in order to ensure correct centering,
the isocentre interest point needed to be shifted to 0.5 cm, along with the other interest points for
OOAR measurements.
5. Added multiple interest points at x-positions (for different depths in the phantom) to compare
with commissioning depth data. Depths used were 2 cm, 5 cm, 10 cm, 20 cm, 30 cm, 40 cm, 50 cm,
and 60 cm.
6. Adjusted prescription to a fixed 2000 MU in order to maintain a constant output for all depths
and off axis distances (OADs), and to reduce impact of noise from small statistical fluctuations.
7. Set beam parameters to the usual TBI treatment conditions with gantry angle 90◦, 45◦ collimator
angle and 40 cm× 40 cm field size set at the isocentre interest point.
8. Varied the off-axis distance by moving the isocentre interest point by 10 cm in the y-direction and
in various distances (2 cm, 5 cm, 10 cm, 20 cm, 30 cm, 40 cm, 50 cm, and 60 cm) in the x-direction
to record the depth-dose at each off-axis distance to determine TPR.
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9. Determined the OOARs for each point using the reference depth at 10 cm and 0 cm off-axis using
Eq. 2.16.
10. From these OOARs, graphing TPRs and profiles for each OAD and depth respectively was done
to compare with our commissioning data.
11. Four different phantoms were created for measurements for the varying depths (30 cm× 30 cm× 30 cm,
40 cm× 30 cm× 30 cm, 50 cm× 30 cm× 30 cm, and 60 cm× 30 cm× 30 cm) to ensure that a direct
comparison between Monaco data and the commissioning results could be made since during com-
missioning additional build up material was added on at each measurement point, rather than
having a 60 cm× 30 cm× 30 cm phantom and varying the measurement points.
12. For depths 40 cm, 50 cm, and 60 cm, an additional 5 cm× 28 cm× 30 cm structure of 0.01 relative
electron density to water was created to reduce the point dose uncertainty in Monaco. Without
this object, sometimes the marker at this maximum depth or measurement point in Monaco would
be at the boundary between the block phantom and air, causing larger than expected uncertainties
by an order of magnitude at this point. These uncertainty reducing objects did not change the
mean or total dose to the point. This object is shown in Fig. 4.1 as the green object.
13. Calculation variables used were a 0.5 cm grid spacing, for MC a 1.00 % statistical uncertainty per
calculation was used with 2500 MU for additional constrained uncertainty. Anything finer than
the 0.5 cm grid spacing would cause Monaco to crash.
Figure 4.1: Monaco Phantom Setup example with 40 cm× 30 cm× 30 cm phantom illustrating the set
up of the beam, external volumes, block phantom, and uncertainty reducing object.
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Fig. 4.1 illustrates the phantom set up in Monaco using the 40 cm× 30 cm× 30 cm as the example as
this shows the point-dose uncertainty reducing structure (green contour) explained in 12. The external
volume created in step (2) did not contribute any difference to the point doses, this was verified by
moving these volumes such that they were directly next to the phantom (positions z = 15.5 cm and
z = −14.5 cm which made no difference to the point doses. It was also tested via comparing point doses
with two planes at positions y = 109.5 cm and y = −109.5 cm with a beam at 100 cm SSD, to with no
planes at 100 cm SSD. The point doses in this case were also identical.
4.1.2 Results
4.1.2.1 MC Model
Modelled dose data using the MC model described in the methods above was tabulated and OOARs
from Eq. 2.16 determined. These OOARs were plotted as a function of off-axis distance and depth so
that the profiles and TPRs could be evaluated qualitatively.
(a) (b)
Figure 4.2: Dose from Monaco’s MC model normalized to the output point for various OADs and depths,
plotted against OAD and depth for (a) T1 treatment room and (b) T2 treatment room. Profiles and
TPRs are shown by these 3D plots with uncertainty bars with a 95 % confidence interval plotted for
each measured point in black.
Fig. 4.2 shows qualitatively, Monaco’s MC model poorly represents a dose profile and TPR for all
depths and OADs. For both T1 and T2 the MC model appears noisy, with T1 having significantly large
error bars relative to the normalized dose.
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4.1.2.2 CCC Model
Modelled dose data using the CCC model described in the methods above were tabulated and OOARs
from Eq. 2.16 determined. These OOARs were plotted as a function of off-axis distance and depth so
that the profiles and TPRs could be evaluated qualitatively.
(a) (b)
Figure 4.3: Dose from Monaco’s CCC model normalized to the output point for various OADs and
depths, plotted against OAD and depth for (a) T1 treatment room and (b) T2 treatment room. Profiles
and TPRs are shown by these 3D plots with uncertainty bars with a 95 % confidence interval plotted
for each measured point in black.
Fig. 4.3 shows qualitatively, Monaco’s CCC model represents a reasonably accurate dose profile and
TPR for all depths and OADs. Unlike with the MC model, the CCC model has smooth profiles and
TPRs, which is what we would qualitatively expect for a homogeneous block phantom.
4.1.3 Discussion
An attempt to model wall backscatter in Monaco was also done for both T1 and T2 geometries. Unfortu-
nately due to the large size of the surrounding walls at these extended SSDs these attempts would cause
Monaco to reach maximum memory and CPU utilization and persistently crash after a long (20 min)
computation time. Therefore given the memory (32 gb available) and processor constraints available,
the wall could not be modelled in Monaco with either T1 or T2 geometries. Wall scatter contribution
was however measured empirically as shown and discussed in Sec. 5.3.
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Anthropomorphic Phantom
Validation of the Monaco model in an anthropomorphic phantom was crucial for determining whether
Monaco could be implemented as a TPS for TBI treatments. The best available heterogeneous phan-
tom at Christchurch Hospital is the RANDO phantom (Fig. 4.4), which includes appropriate density
materials for lungs, bone and other tissues to provide a model which was as close as possible to a human
patient. A CT of this phantom was readily available for importing into Monaco to calculate doses for
comparison to measured data and existing spreadsheet calculated midline doses.
Figure 4.4: Stock photo of the Alderson RANDO phantom.1
This section will discuss the methods of modelling the RANDO phantom at eSSD in Monaco, along
with obtained results in preparation for comparison to measured data in Ch. 6 and a discussion about
TPS limitations. In addition, spreadsheet calculated midline doses will also be compared with Monaco
results to see how well Monaco compares with existing treatment planning. Since it was previously
determined by the block-phantom geometry that the MC algorithm was noisy and poorly represented
profiles and TPRs, the MC algorithm was not evaluated for the RANDO phantom and only the CCC
algorithm will be used for determination of dose in the RANDO phantom.
Chapter 4. Treatment Planning System Modelling at eSSD 42
4.2.1 Methods
To compare point doses in Monaco to those determined from film, diode, and farmer chamber mea-
surements (discussed in Sec. 5.5), and those calculated with the spreadsheet, the following steps and
procedures were taken.
1. A CT of RANDO was imported into Monaco.
2. An external volume of smallest relative electron density to water (0.01) with dimension (SMD −
100 cm)× 60 cm× 1 cm [x, y, z] was created, which encapsulated our internal structures. This slice
was was placed as far away (in the z-direction) as possible from both the internal structures and
the beam. This external volume allowed for the extending of the allowed SSD in Monaco without
perturbing the dose delivered. Fig 4.5 best illustrates the complete setup of structures.
3. Two spoilers of thickness 2 cm were created with internal separation of 43.7 cm and external sep-
aration of 47.5 cm with the spoiler on the left side of RANDO being right up against RANDO’s
shoulder so that modelled results represented measurement setup. These two spoilers had electron
densities of 0.993 and 0.992 for T1 and T2 respectively as discussed in Sec. 2.4.
4. Ricebags were modelled by creating a volume extending from the most superficial point of the
phantom through to the most inferior, and the most anterior through posterior. The lateral
bounds of the volume were 1.5 cm space between the volume and the spoilers on either side, this
was to account for an estimated 1.5 cm of ricebag packing inefficiency being air-gaps within and
between the ricebags. The ricebags were set to electron densities of 0.891 and 0.880 for T1 and
T2 respectively as discussed in Sec. 2.4.
5. Multiple points of interest were placed at 2.5 cm depth divisions between several key slices in
RANDO for comparison to film measurement. Key slices were the head (slice 3-4), neck (slice
9-10), chest (slice 17-18), umbilicus (slice 30-31) and groin (slice 34-35).
6. Points of interest were also placed at the entrance and exits of the head (slice 2), neck (slice 9), chest
(slice 15), umbilicus (slice 27), and groin (slice 35) slices for comparison to diode measurements.
These exact points of measurement were along the approximate middle (AP) of RANDO. Of note
are that these differ from those used for the film comparison, so results may vary slightly.
7. Additionally points of interest were also placed at the half-way point between interest points used
for diode comparisons, these would represent the midline doses for comparison to the spreadsheet
and the farmer chamber measurement (taken at the groin).
8. Two beams on either side of RANDO were created, both had 45◦ collimator angles and their
gantry angles were 90◦ and 270◦ for the right and left fields respectively.
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9. Only the CCC calculation algorithm was evaluated here as it was found the MC model was too
noisy for clinical viability. The CCC variables used were a 0.5 cm grid spacing, 1500 MU for T1
comparison and 2400 MU for T2 comparison.
10. The left and right fields were computed individually, with the results averaged.
Figure 4.5: Monaco Anthropomorphic phantom setup demonstrating structures discussed in method
points 1-4.
The complete setup of the RANDO phantom in Monaco is best illustrated by Fig. 4.5. The spoilers,




Doses were determined for various depths in RANDO using methods above. These doses were to be
compared with measured film data to evaluate the CCC model in a heterogeneous phantom. Only a
left beam was used for the dose calculation as this was mirrored by measurement only being made using
the left field.
Fig. 4.6 illustrates our depth doses in Monaco for various slices in RANDO in both T1 and T2.
Qualitatively the depth dose curve looks as we would expect for homogeneous media, however for
heterogeneous media these depth dose curves seem to be overly simplistic.
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(a) (b)
Figure 4.6: Monaco determined depth dose distributions with various slices in RANDO for (a) T1
treatment room and (b) T2 treatment room.
4.2.2.2 Diode Comparison
To compare our Monaco model to diode measured results in Ch. 5 and Ch. 6, we needed to determine
dose at the corresponding points where diodes would be placed. These points were placed as discussed
in the methods, and doses for both T1 and T2 models were computed for both left and right beams,
1500 MU and 2400 MU were used for T1 and T2 respectively as these approximately gave 1 Gy dose to
the midline. These monitor units would also be delivered for the corresponding measured dose for direct
comparison between the model and measurement later in Ch. 6.
Region
Depth (cm) Head Neck Chest Umbilicus Groin
Left ENT 0.412 1.275 1.847 1.717 1.715
Left EXIT 0.576 1.015 0.715 0.674 0.594
Right ENT 0.570 1.138 1.713 1.718 1.764
Right EXT 0.547 0.900 0.648 0.673 0.625
Average ENT 0.491 1.207 1.780 1.718 1.740
Average EXIT 0.562 0.958 0.682 0.674 0.610
Table 4.1: T1 Table of Monaco entrance (ENT) and exit (EXIT) doses (in Gy) for various points where
diodes were placed.
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Region
Depth (cm) Head Neck Chest Umbilicus Groin
Left ENT 1.456 1.387 1.749 1.621 1.591
Left EXIT 0.962 1.109 0.788 0.736 0.657
Right ENT 1.253 1.267 1.636 1.613 1.648
Right EXT 0.819 0.996 0.722 0.726 0.681
Average ENT 1.355 1.327 1.693 1.617 1.620
Average EXIT 0.8905 1.053 0.755 0.731 0.669
Table 4.2: T2 Table of Monaco entrance (ENT) and exit (EXIT) doses (in Gy) for various points where
diodes were placed.
Tables 4.1 and 4.2 give the Monaco simulated doses at the entrance and exit points of the head,
neck, chest, umbilicus and groin regions (exact slices of points provided in methods). An average of the
left and right fields are also computed for comparison to measurement.
4.2.2.3 Midline and Peak Lung Doses
To compare Monaco with existing spreadsheet calculations and the groin farmer chamber measurements,
midline doses were also computed for points along the midline which corresponded to points sampled
in the spreadsheet. Doses along the midline were computed for the head, neck, chest, umbilicus and
groin. Interest points were placed directly between the entrance and exit points placed for the diodes
comparison. Additionally the peak lung doses were determined using an interest point at the closest
point in the lungs to the beam.
Region
Depth (cm) Head Neck Chest Umbilicus Groin
Left Field 0.660 1.138 1.181 1.097 1.045
Right Field 0.569 1.013 1.081 1.099 1.083
Average 0.615 1.076 1.131 1.098 1.064
Table 4.3: T1 Monaco Midline doses (in Gy) for various regions determined for both left and right fields
and averaged.
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Region
Depth (cm) Head Neck Chest Umbilicus Groin
Left Field 1.192 1.221 1.205 1.111 1.060
Right Field 1.021 1.102 1.106 1.105 1.086
Average 1.107 1.162 1.156 1.108 1.073
Table 4.4: T2 Monaco Midline doses (in Gy) for various regions determined for both left and right fields
and averaged.
Midline doses in Monaco for T1 and T2 are shown in Tables 4.3 and 4.4 respectively. Doses are
determined for both the left and right fields and averaged to determine the average midline dose deter-
mined in Monaco. The peak lung was determined by combining the average entrance and exit doses
from Sec. 4.2.2.2 and then dividing by two (as treatment is bilateral). For T1 and T2 peak lung doses
were determined to be 1.231 Gy and 1.224 Gy respectively.
4.2.2.4 Spreadsheet Dose Comparison
Dose differences were calculated using Eq. 2.17, where D1 were the spreadsheet midline doses and D2
were the average of the left and right field Monaco midline doses from Tables 4.3 and 4.4.
Region
Depth (cm) Head Neck Chest Umbilicus Groin
T1 Midline Dose (Gy) 0.961 1.077 1.179 1.090 1.070
T2 Midline Dose (Gy) 1.103 1.114 1.168 1.083 1.078
T1 DD (%) 36.004 % 0.093 % 4.071 % -0.729 % 0.561 %
T2 DD (%) -0.361 % -4.131 % 1.027 % -2.256 % 0.464 %
Table 4.5: Spreadsheet calculated midline doses for T1 and T2, along with dose differences between
spreadsheet calculated midline doses and averaged left and right field Monaco determined midline doses
The spreadsheet calculated peak lung doses for T1 and T2 were 1.200 Gy and 1.170 Gy respectively.
Therefore T1 and T2 have respective peak lung dose DDs between the spreadsheet and Monaco of
2.518 % and 4.412 %. It is shown by Table 4.5 that T2 has a clinically acceptable agreement between
spreadsheet calculated and Monaco determined doses. For T1 the only region where we see disagreement
is the head, this is most likely due to the head region being in the beam’s peripheral steep dose gradient
region (penumbra). The head region for T1 being in the penumbra is not as significant as other doses due
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to the greater variation of dose in the penumbral region. In most cases Monaco seems to overestimate
the dose to the midline relative to the spreadsheet, there are only three points where Monaco predicted
midline doses are less than the spreadsheet: the groin region for both T1 and T2, and the chest region
for T2. Nevertheless with the exception of the T1 head dose, the predicted midline doses and peak
lung doses are all within clinically acceptable agreement between spreadsheet calculated and Monaco
determined doses. Verifying by comparison to actual measurements covered in the next chapter are
necessary so that appropriate conclusions can be drawn in Ch. 6.
Chapter 5
Linac Measurements
This chapter provides introductions, methods, and results for measurements made with the linacs in
TBI conditions. First we look at quantifying the monitor unit drifting of the linac, followed by deter-
mining the field symmetry and impact of wall scatter. Dose profiles and TPRs are then determined
from measurements in a block-phantom, and finally point doses in an anthropomorphic phantom are
measured. The results from this chapter are then subsequently used in Ch. 6 for comparison to the
TPS model.
Monitor Unit Drifting and Fluctuation
During testing of the PMD, it was discovered that there was considerable drifting of the dose rate
(MU/min) on both T1 and T2 treatment machines over a time span of several minutes up to a steady
state where small fluctuations (±1 MU) were observed. Since charge rate was the quantity measured
when using the PMD, to fully understand the uncertainty of future measurements, it was necessary to
quantify the dose rate drifting both in terms of the time to reach a steady state dose rate tḊSS along with
the steady state variation σḊSS . The steady state variation is then expressed as the relative uncertainty





Since many of the measurements using the PMD were done by measuring dose rate, it is important
to have quantified the uncertainty resulting from the fluctuation from the linac, as well as knowing the
appropriate time to begin measurement for each linac.
Measurement of monitor unit fluctuation in both T1 and T2 was done using an NE2571 farmer
chamber with an appropriate brass buildup cap for each energy (2 mm and 2.5 mm wall thickness for
10 MV and 15 MV respectively), held in-air using a metal retort stand. The chamber was then attached
via triaxial cable to the PTW electrometer and the electrometer then plugged in to a laptop via RS232
to USB. Charge rate was then continuously readout via TBIControl’s electrometer read discussed in
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Sec. 3.3.4. Resulting data was then analysed using Matlab to determine tḊSS , σḊSS , µḊSS and calculate
ur.
(a) (b)
Figure 5.1: T1 graphs of (a) monitor unit drift and fluctuation displaying points of determined steady
state and mean, and (b) monitor unit fluctuation histogram for t > tḊSS showing a Gaussian distribution
and fit with fitted quantities σḊSS , µḊSS , and CV .
(a) (b)
Figure 5.2: T2 graphs of (a) monitor unit drift and fluctuation displaying points of determined steady
state and mean, and (b) monitor unit fluctuation histogram for t > tḊSS showing a Gaussian distribution
and fit with fitted quantities σḊSS , µḊSS , and CV .
Fig. 5.1 and Fig. 5.2 show the approximate tḊSS is 200 s for T1 and 120 s for T2. The mean, standard
deviation and coefficient of variations are also displayed on the respective histograms which show the
Gaussian distribution of charge rate data. The relative uncertainty of charge rate at steady-state was
considered the population type A uncertainty (uncertainty types and their combination are discussed in
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Appendix B) of measured charge rate when using the PMD. This was therefore used as the total type
A uncertainty for measurement of charge rate as it provided the spread of values around the maximum
for the approximate population of measured charge rates.
Symmetry
One of the key assumptions made when making measurements using the PMD is that our radiation
beam is symmetrical. IEC 60976 provides a standard called the point difference quotient (PDQ) which
is a measure of beam symmetry. The PDQ is given by Eq. 5.2, this PDQ has been modified from the










Beam symmetry data was measured at 2.5 cm and 3 cm depths in a 30 cm× 30 cm× 30 cm solid water
block phantom for T1 and T2 respectively. The respective depths were selected for two reasons. Firstly
they were the zmax depths for T1 and T2, therefore TCPE existed. Secondly the minimum possible
depth was chosen where TCPE existed such that flattening of the beam from interactions with the
phantom was minimal. The measurements were taken in 2 cm divisions off axis with 10 s measurement
time using TBIControl’s step and record mode (Sec. 3.3.5).
Two analyses were performed with respect to symmetry data: the zeroed point difference quotient
given by Eq. 5.2, and the symmetry given by simply the left half of the field subtracted from the right
half given by Eq. 5.3 below. Eq. 5.2 gives us the overall symmetry of our field, whilst Eq. 5.3 gives us





The field symmetries of T1 and T2 are plotted in Fig. 5.3 and Fig. 5.4 respectively. From the
plotted symmetries it is shown that within the clinically useful field sizes, T1 and T2 have a maximum
asymmetries of (2± 1) % and (2± 1) % (with 95 % confidence intervals) respectively. AAPM Task
Group 40 (TG-40)47 and the updated Task Group 142 (TG-142)48 reports on quality assurance provide
a 3 % tolerance for beam symmetry.
The dose symmetry of a field is affected by many factors, including small beam steering deviations
onto the flattening filter, and small variations in collimator jaw positions to name a couple. These
variations usually cause beam hardening or softening to one half of the beam, therefore resulting in
superficial dose asymmetries between the two halves of the beam. At greater depths, these asymmetries
become less significant49 as lower energy components of the beam deposit dose superficially.
The measurement of symmetry was taken at the shallowest possible depths where TCPE existed for
T1 and T2. At greater depths the beam would become more symmetric. Our measurements show given
the uncertainty, that over the clinically useful field size the beam symmetries of T1 and T2 are both
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within tolerance and therefore we can assume beam symmetry. This provides a justification for why
profiles will only required to be measured for one half the clinically useful field shown later in Sec. 5.4.
(a)
(b)
Figure 5.3: Profile symmetry graphs determined using data measured on T1 calculated using two
different methods. (a) The zeroed IEC 60976 standard given by Eq. 5.2. (b) The symmetry from the
right half of the field minus the left half normalized to the right half of the field.
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(a)
(b)
Figure 5.4: Profile symmetry graphs determined using data measured on T2 calculated using two
different methods. (a) The zeroed IEC 60976 standard given by Eq. 5.2. (b) The symmetry from the
right half of the field minus the left half normalized to the right half of the field.
Wall Scatter
Backscattered radiation from the reinforced concrete wall behind the couch in the beam-line was im-
portant to quantify. Since the Monaco TPS model could not incorporate wall scatter as discussed in
Sec. 4.1.3, it was necessary to determine the impact backscatter has on the measurement of profiles
and TPRs in order to determine whether the lack of modelling this in Monaco would be a significant
impediment to achieving an accurate beam model.
Radiation backscatter was measured in-air using a farmer chamber with an appropriate build up cap
at various distances from the wall to the SMD and off-axis distances. For each measurement point, two
quantities were measured: the dose rate with no shielding ḊSS (dose rate of source + scatter), and the
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dose rate with 58.4 cm of lead shielding blocking the chamber from the primary beam, ḊS (dose rate
of wall scatter). The lead shielding had dimensions of 58.4 cm× 10 cm× 5 cm, made up of the smallest
sized blocks available so that the field projected on the wall was perturbed as little as possible. For
off-axis distances the effective displacement of the front lead block (the angle which the lead had to be





Where OAD is the off-axis distance, SCD is the source-chamber distance, Llead being the length of
lead 58.4 cm used, and ∆Xmax is the maximum horizontal displacement of the lead, at distance Llead
from the chamber. Fig. 5.5 best illustrates how this effective displacement was used to align the lead
blocks to appropriately shield the farmer chamber when making measurements off-axis.
(a) (b)
Figure 5.5: Experimental set up of wall scatter measurements. (a) Shows the chamber set up with the
retort stand, maximum displacement markings and guide lines for the placement of lead bricks in-front
of the chamber. (b) An example measurement of wall scatter with the lead bricks placed along the guide
lines.
To determine the relative (%) wall scatter Swall at each point the wall scatter dose rate needed to
be normalized to the dose rate of the source. Since the measurement without lead was of the combined
source and wall scatter, the wall scatter needed to be subtracted from this such that the wall scatter
could be normalized to the source only and thus would not be an underestimate of the wall scatter.
Relative wall scatter was determined using Eq. 5.5





Where shielded and non-shielded dose rates were calculated using Eq. 2.12.
SCD at isocenter (cm)
OAD (cm) 341 348 358 368 378 388
0 3.2± 0.1 3.3± 0.1 3.5± 0.1 3.7± 0.1 3.9± 0.1 4.0± 0.1
25 2.2± 0.1 2.3± 0.1 2.7± 0.1 3.0± 0.1 3.1± 0.1 3.5± 0.1
50 2.5± 0.1 2.6± 0.1 2.8± 0.1 3.0± 0.1 3.3± 0.1 3.9± 0.1
75 1.8± 0.1 1.9± 0.1 2.3± 0.1 2.6± 0.1 3.1± 0.1 3.6± 0.1
Table 5.1: Relative wall scatter (%) for T1 at various different source-chamber and off-axis distances.
SCD at isocenter (cm)
OAD (cm) 432.6 437.1 447.1 457.1 467.1
0 3.3± 0.1 1.0± 0.1 1.6± 0.1 1.8± 0.1 1.8± 0.1
25 2.3± 0.1 0.9± 0.1 1.5± 0.1 1.7± 0.1 1.9± 0.1
50 2.6± 0.1 0.8± 0.1 1.5± 0.1 1.8± 0.1 1.7± 0.1
75 1.9± 0.1 0.8± 0.1 1.6± 0.1 2.4± 0.1 2.0± 0.1
Table 5.2: Relative wall scatter (%) for T2 at various different source-chamber and off-axis distances.
It was important to also determine the approximate energy range of the backscattered photons from
the wall. A simple Matlab model of wall backscatter from Compton scattered photons was created
using Eq. 2.3 to determine the maximum energy of scattered photons we could expect for various
measurement points along the SMD.
The energy of Compton scattered photons are only considered here as other processes or scattering
events which could contribute dose to a point at depth in a phantom were assumed to be negligible.
Rayleigh, Delbrück, Thompson scattering are negligible in the MeV energy range for large angles θ >
40◦ when compared with Compton scattering by differential cross section.23 Processes which produce
charged particles like pair production, photoelectric absorption were also assumed negligible. Since the
depth being considered was 10 cm deep in the phantom (from the wall’s perspective), when taking into
account the range of electrons and positrons, the fact that the rate of energy loss of electrons in high
energy therapeutic electron beams is approximately 2 MeV/cm,22 and the scatter in air between the wall
and the solid water phantom, most if not all electrons would contribute no dose to depths z ≤ 20 cm
in the phantom. Dose resulting from the production of photoneutrons in the wall material was also
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assumed negligible as would only make up a small percentage of an already small percentage, discussed
in Sec. 2.1.1.1. Finally from the arguments discussed, the assumption that only the energy of Compton
scattered photons need to be considered when determining whether depths z ≤ 20 cm in our phantom
need to be corrected for wall scatter is reasonable to make.
Fig. 5.6 and Fig. 5.7 show for a chamber at SMD, the energy of backscattered photons in both
treatment rooms is in the range of 0.25 MeV to 0.36 MeV. When taking into consideration the air scatter
between the wall and the phantom, and attenuation of photons with respect to depth in a phantom, it
is reasonable to assume that wall scatter contributions for depths (measured from the linac side of the
phantom) less than or equal to 20 cm will be negligible. Therefore scattering results will only be applied
for the depths 30 cm and greater, and will not need to be applied for comparison to anthropomorphic
phantoms due to rice bag packing and the beam spoilers.
This measurement of wall scatter is important for the comparison of results between Monaco cal-
culated and linac measured dose profiles in block phantoms. As discussed in Sec. 4.1.3, memory and
processing limitations meant that the wall could not be modelled in Monaco. Therefore measuring
the relative wall scatter provides a factor for which Monaco doses can be corrected to provide a more
accurate comparison with measurement later in Ch. 6.




Figure 5.6: T1 Photon energy from points along the wall in the radiation field projected onto the wall
as received by the detector at SMD. (a) With detector at CAX position. (b) Detector at 25 cm off-axis.
(c) Detector 50 cm off-axis. (d) Detector 75 cm off-axis. (e) Detector 100 cm off-axis. This model is
symmetrical on both axes.




Figure 5.7: T2 Photon energy from points along the wall in the radiation field projected onto the wall
as received by the detector at SMD. (a) With detector at CAX position. (b) Detector at 25 cm off-axis.
(c) Detector 50 cm off-axis. (d) Detector 75 cm off-axis. (e) Detector 100 cm off-axis. This model is
symmetrical on both axes.
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Profiles and TPRs in a Block Phantom
5.4.1 Previous Commissioning Measurements
Data from previous (latest) commissioning measurements were used as a reference to see how the
PMD could improve upon measurement methodology. Previous commissioning measurements were
conducted using a 28.4 cm× 30 cm× 30 cm PTW T41023 water phantom44 with 0.6 cm thick of fitted
red wax and 1 cm of blue solid water to fill in the small gap in the exterior of the tank and build up
to 30 cm× 30 cm× 30 cm total volume.50,51 For depths z > 30 cm additional blue solid water was used
to build up the depth. A NE2571 farmer chamber was placed in a holder within the tank and moved
when necessary to measure doses at depth and off-axis. When performing measurements off-axis and
for some depths the entire water tank and solid water ensemble had to be physically moved, this was
not only a time consuming endeavor per-measurement, but also contributed a significant (±1 cm with
95 % confidence interval) amount of uncertainty with respect to chamber position.
(a) (b)
Figure 5.8: Dose normalized from previous commissioning data to the output point for various OADs
and depths, plotted against OAD and depth for (a) T1 treatment room and (b) T2 treatment room.
Profiles and TPRs are shown by these 3D plots with uncertainty bars (95 % confidence interval) plotted
for each measured point in black.
Fig. 5.8 shows the previous commissioning results for T1 and T2. T1’s TPRs and profiles qualita-
tively look as we would expect until we get to 70 cm off-axis where we see the TPR becomes quite noisy
and appears jagged instead of a smooth depth dose we would expect. T2 by contrast was markedly in-
consistent with what a normal TPR should look like throughout all off-axis distances. If profile is looked
at alone, T2 would seem to be normal, however when we plot both together we see that at depths 40 cm
and 50 cm the dose begins to level off, rather than smoothly decreasing as expected. This presented
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an immediate challenge when looked at, and was resolved by repeating measurements for depths 40 cm
and 50 cm using identical apparatus under conditions described above. It was found that the previous
commissioning data was about 14 % greater than the newly acquired data.
5.4.2 Measurements Using the PMD
Measurements of profiles and TPRs in T1 and T2 used the PMD in step and record mode (discussed in
Sec. 3.3.5) with a 10 s record time for each point off-axis. The ambient temperature and pressure inside
T1 and T2 were also recorded at the start and end of profile acquisitions. Variations in temperature
and pressure were found to be less than 0.2 ◦C and 0.5 hPa respectively for all profile measurements in
T1 and T2.
Absorbed dose to water is determined using TRS-398’s Eq. 2.12 as discussed in Sec. 2.1.4.1. The
final quantity to be determined is the OOAR given by 2.16, substituting the Eq. 2.12 into Eq. 2.16
yields Eq. 5.6.
OOAR(hν,A, z, x) = 
ND,w,Q0 ×MQ(z, x)×kQ,Q0 × kTP (z, x)× ks ×kpol

ND,w,Q0 ×MQ(10 cm, 0 cm)×kQ,Q0 × kTP (10 cm, 0 cm)× ks ×kpol
(5.6)
Since ND,w,Q0 , kQ,Q0 , kpol and ks are identical for the output point and points off-axis these terms
cancel. Given the maximum variations in temperature and pressure during measurement, using Eq.
2.13 the maximum change in kTP would be approximately 0.03 % given T and P are of the order of T0
and P0 respectively. Therefore due to ∆kTP being insignificant, along with the fact that the ratio of
charge is interchangeable with the ratio of charge rate, we can finally simplify our calculation of OOAR
to Eq. 5.7.
OOAR(hν,A, z, x) =
Q̇(z, x)
Q̇(10 cm, 0 cm)
(5.7)
Where Q̇(z, x) is the charge rate at depth z and off-axis distance x, and Q̇(10 cm, 0 cm) is the charge
rate at the output point, z = 10 cm and x = 0 cm.
Fig. 5.9 shows both our measured profiles and TPRs for both T1 and T2 treatment rooms. The
uncertainty of these profiles and TPRs are determined by combining the type A relative uncertainty of
dose rate fluctuation (discussed in Sec. 5.1), and relative type B estimated uncertainty associated with
geometrical setup uncertainties, equipment variation and small changes in ambient conditions. These
uncertainties are then combined using Eq. B.5.
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(a) (b)
Figure 5.9: Charge rates from PMD measurement normalized to the output point for various OADs
and depths, plotted against OAD and depth for (a) T1 treatment room and (b) T2 treatment room.
Profiles and TPRs are shown by these 3d plots with uncertainty bars (95 % confidence interval) plotted
for each measured point in black.
5.4.3 DD Comparison
To compare our sets of PMDmeasured profiles and TPRs to the previous commissioning set, DD analysis
was performed. The DD for T1 and T2 was determined using Eq. 2.17 with the previous commissioning
OOARs being subtracted from the PMD measured OOARs.
OAD (cm)
Depth (cm) 0 10 20 30 40 50 60 70 80
2 -1.44 % -1.06 % -0.27 % -0.25 % 0.07 % 0.22 % 0.19 % 1.10 % 5.54 %
5 -0.25 % -0.15 % 0.51 % 0.86 % 1.23 % 1.46 % 1.93 % 2.26 % 10.62 %
10 0.00 % -0.12 % 0.50 % 0.74 % 1.05 % 1.04 % 1.67 % 1.73 % 3.79 %
20 -2.42 % -1.78 % -0.91 % -1.04 % -0.32 % -0.05 % 0.37 % 0.79 % 10.31 %
30 -1.77 % -0.56 % -0.32 % -0.01 % 0.27 % 0.62 % 0.45 % 1.42 % 0.01 %
40 -3.27 % -1.25 % -1.38 % -1.05 % -0.50 % -0.18 % 0.58 % 0.77 % 4.34 %
50 -2.07 % -1.16 % -0.31 % -0.05 % 0.70 % 0.66 % 0.68 % 2.81 % 15.92 %
60 -2.57 % -1.66 % -0.55 % 0.16 % 0.66 % 0.74 % 1.91 % 1.27 % 1.02 %
Table 5.3: T1 DD between OOARs calculated from measured data using the PMD and previous com-
missioning OOARs.
Table 5.3 shows a reasonable DD between previous and current measurement, most DDs within our
clinically useful field size are < 3% with the exception of one point with a DD of −3.27 % which is
acceptable.
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OAD (cm)
Depth (cm) 0 10 20 30 40 50 60 70 80 90 100
2 0.72 % 0.85 % 1.80 % 2.02 % 2.28 % 2.48 % 2.19 % 1.99 % 1.70 % 1.58 % -0.65 %
5 0.76 % 1.39 % 1.33 % 1.74 % 1.80 % 1.93 % 1.91 % 1.77 % 2.58 % 3.39 % 0.28 %
10 0.00 % 1.81 % 1.50 % 1.91 % 2.11 % 1.91 % 2.12 % 2.31 % 2.31 % 2.92 % 1.26 %
20 -0.26 % 0.23 % 0.07 % 0.41 % 0.54 % 0.64 % 0.79 % 0.96 % 1.32 % 2.24 % 0.90 %
30 -0.44 % -0.33 % 0.38 % -0.10 % -0.69 % -0.51 % -0.95 % -1.39 % -1.77 % -1.26 % -2.35 %
40 -14.74 % -14.04 % -14.05 % -13.88 % -14.86 % -14.40 % -14.66 % -14.47 % -13.87 % -13.36 % -14.34 %
50 -15.02 % -14.47 % -14.11 % -13.70 % -13.64 % -13.96 % -13.92 % -14.23 % -14.52 % -13.91 % -13.25 %
60 0.53 % 1.06 % 1.44 % 1.63 % 1.74 % 0.50 % -0.16 % 0.78 % 0.26 % 1.28 % -0.73 %
Table 5.4: T2 DD between OOARs calculated from measured data using the PMD and previous com-
missioning OOARs.
Table 5.4 shows that with an exception of measurements at depths 40 cm and 50 cm, we have a
reasonable DD between previous and current measurement, with only one point where the DD is −3.39 %
which is acceptable. We have discussed that the previously measured data had doses approximately
14% larger than a newly acquired data set under identical conditions. DDs for 40 cm and 50 cm seem to
confirm these approximate overdoses from the previous commissioning data set. It is unclear what may
have caused these overdoses in previous measurement, whether it be positioning error, large changes in
ambient conditions, or equipment setup over the long time (approximately 12 h) these measurements
took. Confidence in the fact that previous measurements were in-fact overdoses came from carefully
(over several hours) remeasuring a couple of doses along the central axis using the same equipment
(water tank setup), where results were less than 1 % different from those measured using the PMD.
Additionally a few sets of measurements using the PMD were carried out over a few months where
differences in results between them were less than 2 %. It is clear that the speed at which the PMD can
carry out commissioning measurements and the improved chamber positioning accuracy provide a huge
benefit, both in time saving and accuracy for conducting profile and TPR commissioning measurements
with block phantoms.
Point Doses in an Anthropomorphic Phantom
Point doses were measured both with film and diodes using the RANDO phantom. In each measurement
case, two spoilers were used, and rice bags were packed around RANDO as tightly as possible stacked
up to the height of the spoilers with 20 cm of rice bags extending from the most superior and inferior
points of RANDO to be as close to a typical clinical set up as possible. This section will discuss the
two different measurement types explored, along with their individual methods, results and discussion.
5.5.1 Film Measurements
Immediately prior to measurement within RANDO, a set of calibration measurements were taken so that
the RGB colour of the film could be calibrated against dose delivered. Eleven 4 cm× 4 cm squares of
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film were cut out and marked with a number at the upper left corner for orientation and dose delivered.
Four cross hairs were also marked at the edges of the film for alignment of the film to the linac’s cross
hairs. Each piece of film was placed beneath 10 cm of blue solid water at isocenter (100 cm SAD with
a 10 cm× 10 cm fieldsize), and were irradiated from 50 MU to 500 MU in 50 MU steps for films 1 to 10
respectively, the zeroth piece of film was not irradiated. The numbered orientation and delivered dose
labelling of the calibration film along with cut direction is best shown by Fig. 5.10a. A farmer chamber
measurement was also taken at 10 cm deep in blue solid water at isocenter under identical conditions
such that the MU could be converted to Gy therefore allowing for a calibration curve of RGB values of
film versus dose to be determined.
(a) (b)
Figure 5.10: Film cut methodology with consistent orientation using labels and numbering at the
upper left hand corner of each film. (a) Shows the numeric labelling of calibration film where numbers
corresponded to the increments in dose, (b) shows the labelling of the measurement film which labelled
the slice number and direction the wall was facing for the film closest to the wall.
For measurement within RANDO, each piece of film was cut into different equally sized strips with
their orientation marked, and slotted into various transverse slices in RANDO. The orientation direction
was identical to the calibration film. The orientation was marked with the slice number in the upper
left corner, along with wall being labelled on the film which would be closest to the wall, this is best
illustrated by Fig. 5.10b. Five different slices were used for representation: 3-4 (head), 9-10 (neck), 17-
18 (mid chest), 30-31 (umbilicus), 34-35 (groin). Due to the transverse width of RANDO, two different
film slices were required for all but the head and neck measurement region so that a PDD could be
determined through RANDO, these two films were taped together and did not overlap. When the films
were slotted into place, the entrance and exit points of RANDO were drawn using a marker on all films.
Due to timing constraints and to keep everything consistent between TPS modelling and measure-
ment, only a single left field was used. 1500 MU was delivered for T1 and 2400 MU was delivered for
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T2.
(a) (b)
Figure 5.11: Film measured depth doses in RANDO in (a) T1 treatment room and (b) T2 treatment
room.
Films were analysed using FilmQA Pro (Ashland LLC), using triple channel correction with the blue
channel correcting for film density variation. The resulting depth doses are shown by Fig. 5.11. Quali-
tatively these depth doses appear noisy, though this could simply be a consequence of inhomogeneities
in RANDO.
5.5.2 Diode Measurements
A set of diode measurements were also taken to compare in-vivo dosimetry commonly measured during
patient treatment to Monaco results. Diodes were placed in accordance to local practice in-vivo positions
Sec. 2.4.4 with the single groin diode replaced with an entrance and exit groin diode and the exclusion of
the thighs, calves and ankles as these were not part of the RANDO phantom. Since diodes representing
the exit doses were facing away from the beam, a diode orientation factor (DOF) had to be determined
so that exit doses could be corrected to truly reflect dose to the point. This orientation factor was
measured using 5 different diodes between slices 20-21 at the exit of the phantom, diodes were placed
orientated toward the beam with dose measured and then flipped to face away from the beam at the
same point with dose measured. The orientation factor was then calculated by averaging the ratios of
dose toward the beam and dose away from the beam.
DOFT1 = 1.20± 0.02,
DOFT2 = 1.16± 0.02.
The diode orientation factor was measured at the exit of RANDO under full scatter conditions with
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ricebag packing and spoilers so that a true representation of exit dose scaling could be attained which
would take into account beam hardening and scatter.
Region
Field + Diode Head Neck Chest Umbilicus Groin
Left ENT 0.630 1.297 1.834 1.698 1.668
Left EXIT 0.564 0.931 0.828 0.655 0.670
Right ENT 0.377 1.190 1.667 1.584 1.814
Right EXT 0.539 1.027 0.721 0.668 0.709
Average ENT 0.504 1.244 1.751 1.641 1.741
Average EXIT 0.551 0.979 0.775 0.662 0.689
Table 5.5: T1 exit-corrected diode measurements of dose (Gy) with TBI setup using the RANDO
phantom, with the left and right fields averaged. ENT and EXIT are abbreviations for the entrance
and exit respectively where the entrance is the closest diode to the beam at the entrace of RANDO and
exit is the diode on the contralateral side.
Region
Field + Diode Head Neck Chest Umbilicus Groin
Left ENT 1.340 1.382 1.828 1.639 1.680
Left EXIT 0.824 1.040 0.905 0.700 0.736
Right ENT 1.482 1.431 1.689 1.588 1.618
Right EXT 0.906 1.099 0.848 0.750 0.732
Average ENT 1.411 1.407 1.759 1.614 1.649
Average EXIT 0.865 1.070 0.876 0.725 0.734
Table 5.6: T2 exit-corrected measurements of dose (Gy) with TBI setup using the RANDO phantom,
with the left and right fields averaged. ENT and EXIT are abbreviations for the entrance and exit
respectively where the entrance is the closest diode to the beam at the entrace of RANDO and exit is
the diode on the contralateral side.
Tables 5.5 and 5.6 show the left and right field entrance and exit doses on RANDO along with the
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left and right field entrance and exit doses averaged for T1 and T2 respectively. Uncertainties for these
doses are ±2 % (95 % confidence interval) given by the calibration tolerances and having made repeated
measurements to confirm. The approximate peak lung dose with bilateral fields can be calculated by
the sum of the average entrance and exit doses divided by two. For T1 and T2 the approximate peak
lung doses are 1.253 Gy and 1.318 Gy respectively. These results are useful for making comparisons to
Monaco modelled entrance and exit doses (from Sec. 4.2.2.2) later in Ch. 6.
5.5.3 Farmer Chamber Measurements
A farmer chamber was placed along the midline in the groin region taped in-place directly between
RANDO’s thighs. The total charge was measured three times for both the left and right fields and
averaged, temperature and pressure were also measured for calculation of kTP . Absorbed dose to water
was then calculated using Eq. 2.12. The results for these measurements are:
Dw(T1) = (1.04± 0.02) Gy,
Dw(T2) = (1.07± 0.02) Gy.
Dw(T1) and Dw(T2) are the averaged calculated absorbed doses to water.
Chapter 6
Discussion
Up until now results from TPS modelling of block and anthropomophic phantoms in TBI conditions
(Ch. 4) and linac measurements in TBI conditions (Ch. 5) have been presented. The goal of this
chapter is to compare, contrast and discuss the treatment planning modelled data with measured data
so we can evaluate Monaco and the existing spreadsheet calculation for TBI planning. Measured and
modelled results will be compared on a DD basis using Eq. 2.17 where D1 corresponds to measured
results, and D2 are TPS modelled results. Since our linac measurements primarily used the PMD which
was evaluated in Ch. 3, we will also be discussing the use of the PMD in relation to the data acquired.
Firstly measured and modelled profiles and TPRs in the block-phantom geometry will be compared
using both the CCC and MC algorithms for both T1 and T2 treatment rooms. Next point doses and
depth doses will be compared in an anthropomorphic phantom for select slices, with the aim of achieving
a broad evaluation of DD between film, diode and Farmer chamber measurements and the TPS CCC
model of RANDO. Comparisons to the existing spreadsheet will then be made for discussions around
existing treatment planning. Finally an overall discussion and summary will be made discussing the
results of this thesis as a whole which will lead into the conclusion and future research in this area.
Block Phantom
For comparison of the TPS model with linac measurements in a block-phantom geometry, the measure-
ment of profiles and TPRs in Sec. 5.4.2 were corrected by interpolated wall scatter results for depths
30 cm to 60 cm as discussed in Sec. 5.3. The wall scatter-corrected measurements were then compared
with TPS modelled results by DD comparison using Eq. 2.17 where D1 corresponds to normalized mea-
sured doses and D2 are normalized modelled doses in Monaco. Monaco modelled results were clinically
acceptable if DD < 6 %, this is because the maximum uncertainty of the measured and modelled results
when combined was 4 % (with 95 % confidence interval), therefore if the DD was greater than 6 %, then
there may exist some values where the true value of DD may exceed 10 % given the uncertainty. This
would therefore be outside of the TG-17 required TBI accuracy13,14 and hence why 6 % was chosen as
66
67 6.1. Block Phantom
the cut-off for clinically acceptable agreement.
This section will evaluate the MC and CCC Monaco models in both T1 and T2 treatment rooms
with the aim of quantitatively determining the agreement between profiles measured in Ch. 5 and those
calculated using Monaco in Ch. 4. This determines whether using Monaco is feasible at eSSD with
simple phantom and setup geometries, to provide justification for or against making comparisons in
more complex (heterogeneous) media with an anthropomorphic phantom.
6.1.1 MC Model Comparison
Due to the qualitative noisy appearance of the MC model as discussed in Sec. 4.1.2.1, only tabulated
DD comparisons were analysed for the MC model rather than graphical analysis.
OAD (cm)
Depth (cm) 0 10 20 30 40 50 60 70 80 90 100
2 10.78% 17.13% 4.10% 15.86% 12.20% 1.53% 16.09% 10.48% 5.50% -16.50% -35.88%
5 -11.01% 14.33% -1.73% 13.80% 21.84% 5.65% 8.97% 10.09% 5.69% -16.54% -53.91%
10 0.00% 10.82% -4.58% 17.92% 2.63% 8.68% 10.04% -3.69% 18.14% -9.59% -34.88%
20 -7.97% 16.46% 18.82% 18.77% 0.13% 0.38% 10.03% 19.39% 6.87% -7.86% -26.65%
30 0.64% 13.18% -2.03% 3.04% 17.93% 7.70% -13.60% 1.52% 21.04% -30.12% 67.91%
40 -3.05% -3.13% -7.33% 5.29% 44.51% 9.84% -0.95% 24.06% -7.35% -18.24% 45.92%
50 17.38% 0.50% 19.83% 18.65% 0.93% 16.84% 34.00% 13.03% -1.02% 72.13% 46.84%
60 5.86% 1.03% 14.61% 18.92% 21.58% 39.34% 41.17% 39.40% 7.28% -1.74% 90.76%
Table 6.1: T1 Table of DD between measured and MC modelled OOARs for various OADs and depths
colour coded for specific DD thresholds. Green where DD < 3 %, yellow where DD < 6 %, red where
DD > 6 %.
OAD (cm)
Depth (cm) 0 10 20 30 40 50 60 70 80 90 100
2 -2.40% 1.72% -3.61% 2.26% -8.73% -4.57% 4.24% 8.15% 4.87% -0.42% 6.19%
5 -1.13% -2.31% -3.08% -2.30% -6.04% -3.57% -0.18% 1.76% 5.12% 1.41% 3.22%
10 0.00% -1.73% -3.75% -3.66% -5.66% -5.53% 1.87% -1.54% 4.69% -0.65% 0.32%
20 -2.15% -9.64% -0.96% -5.40% -9.25% -5.55% -5.72% -4.47% -4.94% -0.15% -2.89%
30 -3.57% -10.41% -4.79% -7.00% -12.15% -4.23% -3.53% -5.29% -4.07% -4.42% -7.74%
40 -8.10% -4.64% 6.78% -0.58% -5.37% -3.65% -1.81% -0.60% -2.39% -3.35% 7.37%
50 -4.70% -10.96% -5.24% -2.53% -11.18% -1.60% -12.50% -6.59% -3.97% -17.49% -4.13%
60 -3.55% -3.96% -4.52% -6.21% -0.76% 4.24% -1.35% 6.26% -3.81% -8.31% -1.72%
Table 6.2: T2 Table of DD between measured and MC modelled OOARs for various OADs and depths
colour coded for specific DD thresholds. Green where DD < 3 %, yellow where DD < 6 %, red where
DD > 6 %.
Poor agreements between measured and modelled profiles and TPRs are shown by Tables 6.1 and
6.2 over the entire range of off axis distances and depths for T1 and T2. While there are fewer points
of difference exceeding 6 % in T2 compared with T1, T2 still contains several points of difference which
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could not be characterised. These comparisons show that the MC algorithm cannot be used with the
existing beam model in both T1 and T2 TBI geometries.
6.1.2 CCC Model Comparison
6.1.2.1 T1 Treatment Room
With respect to profiles and TPRs for T1 (shown in Fig. 6.1, Fig. 6.2, Fig. 6.3 and Fig. 6.4 below)
we show with Table 6.3 that either the Monaco TPS model breaks down >80 cm or the measure of
charge rate in the penumbral region has too great of an uncertainty due to steep dose gradients (with
uncertainty in dose being affected significantly more with small uncertainties in chamber localisation)
and the dose rate being much lower relative to the central axis dose. However since the usable field
region for T1 is 120 cm, TPRs modelled only need to be valid to 60 cm off-axis distance. The maximum
DD is 5.77 % (from table 6.3) up to 60 cm off-axis, with the most common DD being in the 3 % range
(median of 3.04 %). The DD results for T1 show clinically acceptable agreement between the Monaco
and measurement over 2 cm to 60 cm depths within the clinically useful field size.
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(a) (b)
(c) (d)
Figure 6.1: T1 Profiles for depths (a) 2 cm (b) 5 cm (c) 10 cm (d) 20 cm, normalized to the point
where output was measured. Profiles, simulated in Monaco (blue), measured with the PMD (red), and
compared by DD (orange). Uncertainty bars represent 95 % confidence intervals.
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(a) (b)
(c) (d)
Figure 6.2: T1 Profiles for depths (a) 30 cm (b) 40 cm (c) 50 cm (d) 60 cm, normalized to the point
where output was measured. Profiles simulated in Monaco (blue), measured with the PMD (red), and
compared by DD (orange). Uncertainty bars represent 95 % confidence intervals.




Figure 6.3: T1 TPRs for OADs (a) 0 cm (b) 10 cm (c) 20 cm (d) 30 cm (e) 40 cm (f) 50 cm, normalized
to the point where output was measured. TPRs simulated in Monaco (blue), measured with the PMD
(red), and compared by DD (orange). Uncertainty bars represent 95 % confidence intervals.




Figure 6.4: T1 TPRs for OADs (a) 60 cm (b) 70 cm (c) 80 cm (d) 90 cm (e) 100 cm, normalized to the
point where output was measured. TPRs simulated in Monaco (blue), measured with the PMD (red),
and compared by DD (orange). Uncertainty bars represent 95 % confidence intervals.
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OAD (cm)
Depth (cm) 0 10 20 30 40 50 60 70 80 90 100
2 -0.42 % 1.15 % 2.18 % 2.40 % 2.93 % 3.35 % 3.55 % 3.25 % 2.20 % 22.67 % -5.41 %
5 -0.59 % 0.90 % 1.60 % 1.88 % 2.36 % 2.72 % 2.77 % 2.36 % 1.19 % 22.10 % 2.62 %
10 0.00 % 0.70 % 1.54 % 1.61 % 2.18 % 2.40 % 2.55 % 1.71 % 0.45 % 17.59 % 3.02 %
20 -1.56 % -0.17 % 0.60 % 0.55 % 1.00 % 1.08 % 0.88 % -0.22 % -1.96 % 8.61 % 9.80 %
30 3.55 % 4.32 % 4.32 % 4.16 % 4.63 % 4.71 % 3.91 % 2.78 % 3.29 % 7.88 % 31.80 %
40 3.41 % 4.51 % 4.65 % 4.71 % 4.64 % 4.45 % 3.68 % 2.25 % 0.73 % 7.92 % 43.53 %
50 4.88 % 5.77 % 5.70 % 5.46 % 5.16 % 4.65 % 2.91 % 1.56 % -0.68 % 7.70 % 51.52 %
60 5.15 % 5.48 % 5.31 % 4.39 % 3.77 % 2.09 % 0.34 % -1.41 % -3.87 % 8.20 % 54.37 %
Table 6.3: T1 Table of DD between measured and CCC modelled OOARs for various OADs and depths
colour coded for specific DD thresholds. Green where DD < 3 %, yellow where DD < 6 %, red where
DD > 6 %.
6.1.2.2 T2 Treatment Room
With respect to Profiles and TPRs for T2 (shown by Fig. 6.5, Fig. 6.6, Fig. 6.7 and Fig. 6.8) it is shown
that the Monaco TPS model breaks down at points 2 cm depth and 90 cm off-axis, 50 cm depth and
100 cm off-axis, and 60 cm depth for off-axis distances greater than 60 cm. Since the usable field region
for T2 is 170 cm, TPRs modelled only need to be validated to 85 cm off-axis distance. The maximum
DD is −10.78 % (from Table 6.4) up to 90 cm off-axis, with the most common DD being in the 1 % range
(median of 1.32 %). The DD results for T2 show clinically acceptable agreement between Monaco and
measurement over 5 cm to 50 cm depths over the clinically useful field size, with 60 cm depth acceptable
up to 60 cm off-axis.
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(a) (b)
(c) (d)
Figure 6.5: T2 Profiles for depths (a) 2 cm (b) 5 cm (c) 10 cm (d) 20 cm, normalized to the point
where output was measured. Profiles simulated in Monaco (blue), measured with the PMD (red), and
compared by DD (orange). Uncertainty bars represent 95 % confidence intervals.
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(a) (b)
(c) (d)
Figure 6.6: T2 Profiles for depths (a) 30 cm (b) 40 cm (c) 50 cm (d) 60 cm, normalized to the point
where output was measured. Profiles, simulated in Monaco (blue), measured with the PMD (red), and
compared by DD (orange). Uncertainty bars represent 95 % confidence intervals.




Figure 6.7: T2 TPRs for OADs (a) 0 cm (b) 10 cm (c) 20 cm (d) 30 cm (e) 40 cm (f) 50 cm, normalized
to the point where output was measured. TPRs, simulated in Monaco (blue), measured with the PMD
(red), and compared by DD (orange). Uncertainty bars represent 95 % confidence intervals.




Figure 6.8: T2 TPRs for OADs (a) 60 cm (b) 70 cm (c) 80 cm (d) 90 cm (e) 100 cm, normalized to the
point where output was measured. TPRs, simulated in Monaco (blue), measured with the PMD (red),
and compared by DD (orange). Uncertainty bars represent 95 % confidence intervals.
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OAD (cm)
Depth (cm) 0 10 20 30 40 50 60 70 80 90 100
2 0.89 % 1.28 % 2.01 % 3.14 % 3.48 % 4.20 % 4.24 % 5.71 % 5.79 % 6.92 % 4.16 %
5 1.25 % 1.34 % 1.63 % 1.87 % 1.94 % 1.87 % 2.14 % 2.93 % 3.91 % 4.30 % 1.45 %
10 0.00 % 0.53 % 0.57 % 0.86 % 1.05 % 0.77 % 1.18 % 2.10 % 2.37 % 2.86 % -0.40 %
20 -0.47 % -0.40 % -0.38 % -0.38 % -0.49 % -0.50 % -0.10 % 0.34 % 0.67 % 0.66 % -2.04 %
30 3.36 % 2.77 % 2.60 % 2.08 % 1.55 % 2.00 % 1.59 % 1.66 % 0.87 % 0.60 % -1.77 %
40 3.29 % 3.30 % 2.74 % 2.45 % 1.94 % 2.15 % 1.77 % 1.55 % 0.39 % -0.10 % -3.18 %
50 3.10 % 2.63 % 2.03 % 1.49 % 0.98 % 0.12 % -0.43 % -1.84 % -3.17 % -4.83 % -7.30 %
60 1.50 % 1.29 % 0.10 % -0.31 % -1.81 % -3.52 % -5.32 % -6.50 % -9.47 % -10.78 % -14.04 %
Table 6.4: T2 Table of DD between measured and CCC modelled OOARs for various OADs and depths
colour coded for specific DD thresholds. Green where DD < 3 %, yellow where DD < 6 %, red where
DD > 6 %.
6.1.2.3 Summary of Block Phantom Comparisons
For both T1 & T2 we had to take into consideration the clinically useful field regions and the depths
of TCPE (discussed in Sec. 2.1.3.1 and Sec. 2.1.4.1). The clinically useful field regions were previously
defined as up to 60 cm & 85 cm (for half the beam), and the depths where TCPE applies are those
above 2.5 cm & 3 cm for T1 & T2 respectively. Measured dose discrepancies for ionisation chambers in
the buildup region are much greater than those measured when TCPE is established.52 Additionally
the AAPM Task Group 53 (TG-53) provides a tolerance for TPS determined point doses which is
large (±20 %)53 in this buildup region. Therefore for conclusions drawn with respect to feasibility,
use of Monaco should be constrained to the depths between 5 cm to 60 cm for T1, 5 cm to 50 cm for
T2, and off-axis distances between 0 cm to 60 cm (T1) and 0 cm to 85 cm (T2). Subsequent modelling
with anthropomorphic phantoms should note these as depth and off-axis positional constraints for the
interpretation of data and potential use for patient dose calculations.
Overall depths between 50 cm and 60 cm are less important clinically to the total dose, since the
patient is treated bilaterally these output doses are weighted significantly less than the input doses
from each side. Additionally, much like the argument made for 2 cm depth, the dose delivered at 60 cm
depth would also be delivered to the perspex panel on the opposite side (maximum treatment side panel
internal separation of 57.5 cm). The comparisons for depths 30 cm to 50 cm also show that there are
greater uncertainties in the surface of the widest region of the patient (i.e around the shoulder furthest
from the beam).
Anthropomorphic Phantom
It has been shown in the previous section that Monaco can effectively predict dose distributions in homo-
geneous phantoms at the eSSDs used clinically, given certain off axis and depth constraints. Following
from this film, diode and farmer chamber dosimetry were used to measure point doses at various depths
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in RANDO, and were compared with Monaco and spreadsheet calculated doses at identical points. The
maximum uncertainties of measurement and modelled doses combined were all approximately 4 % and
hence a 6 % DD was determined to be the cut-off for clinically acceptable agreement between Monaco
and measured results. This section provides a comparison between measured point doses and Monaco’s
CCC and spreadsheet calculated doses so that the Monaco and the existing treatment planning methods
can be evaluated in a heterogeneous phantom. First, point doses measured with film will be compared
with identical points in Monaco. In-vivo point doses measured using diodes and Farmer chambers will
then be compared with Monaco point doses. A comparison will then be made between the existing
spreadsheet calculated midline and peak lung doses to film and diodes measurements are provided along
with contrasting comparisons with those made to Monaco, with the aim of determining the superior
treatment planning approach. Finally comparisons will be summarised to provide a clearer picture of
the conclusions drawn.
6.2.1 Film Comparisons
Differences between Monaco and film measured depth doses are shown by Fig. 6.9 below for T1 and
T2. These comparisons were made using Eq. 2.17 with film measured doses from Ch. 5 being D1 and
Monaco calculated doses from Ch. 4 being D2.
(a) (b)
Figure 6.9: Dose differences between film measured and Monaco modelled depth doses for (a) T1
treatment room and (b) T2 treatment room.
For T1, Fig. 6.9a shows that there are a few regions where Monaco and measured results are not
within clinically acceptable agreement. For the groin, there is no clinically acceptable agreement between
measured film results and Monaco calculated results for all depths in RANDO. The neck region also has
several points of disagreement, and is only clinically acceptable between 7.5 cm to 17.5 cm depths and
at the entrance 0 cm depth. The chest, umbilicus and head regions are regions of best agreement, with
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the chest being clinically acceptable over 0 cm to 22.5 cm depths, the umbilicus is clinically acceptable
over 0 cm to 25 cm depths, and finally the head is clinically acceptable over its entire 15 cm depth.
Similar to T1, T2’s results shown in Fig. 6.9b also show a few regions of significant disagreement.
The groin region only has one point of clinical agreement at the exit depth of 32.5 cm. The umbilicus
region has a range of disagreement between 7.5 cm to 22.5 cm depths and is only clinically acceptable
outside of this range. The chest, neck and head are all within clinically acceptable agreement over their
entire 30.2 cm, 26 cm, and 15 cm respective depths.
There are a few potential reasons why some depths in regions validate where others do not. The
first reason are potential errors in measurement setup both geometrically and with rice bag packing.
The entire RANDO phantom was extremely difficult to setup in a reproducible way when rice bags and
spoilers were included, therefore this may have added in additional uncertainties which may have been
unaccounted (or improperly accounted for the rice bag packing case) for in the model. Additionally
RANDO is not a perfect model of a patient as has a hard exterior shell meaning that rice bags are not
packed as conformally and efficiently compared to an actual patient. These difficulties in setup may
have contributed to additional unexpected uncertainties in the measurements which could cause larger
differences of agreement than expected. A second reason could be errors with calibration of the film,
this is unlikely as the response from all three colour channels qualitatively seemed to be as expected
and uncertainties were used appropriately to account for film processing. However, it is possible that
uncertainties with calibration and processing of film (when used according to protocol) were greater than
shown in literature and this could have contributed to additional discrepancies in dose. Thirdly the CCC
model in Monaco may not appropriately be determining the scatter and absorption from inhomogeneities
correctly at eSSD. It qualitatively looks like DDs are less clinically acceptable in regions where there are
more dense (bony) inhomogeneities distributed through the region like the Groin, Neck and Umbilicus.
Therefore it could be a case where Monaco’s CCC algorithm does not properly consider the scatter and
absorption processes correctly in the dense inhomogeneities and therefore in regions where there are
more distributed throughout there are larger dose discrepancies between measured and modelled doses.
Finally there may be other unknown influencing factors not considered which may have contributed to
additional dose discrepancies between measured and modelled doses.
6.2.2 Diode Comparisons
Comparisons between measured diode results from Sec. 5.5.2 and those determined with similar points
in Monaco from Sec. 4.2.2.2 were made by averaging the doses from the left and right fields for each
point and then calculating the DD using Eq. 2.17 with D1 being diode measured dose and D2 Monaco
modelled dose.
81 6.2. Anthropomorphic Phantom
Region
Comparison Head Neck Chest Umbilicus Groin
T1 Average ENT DD 2.48 % 2.98 % -1.66 % -4.45 % 0.09 %
T1 Average EXIT DD -1.80 % 2.21 % 12.01 % -1.74 % 11.58 %
T2 Average ENT DD 4.00 % 5.65 % 3.75 % -0.22 % 1.79 %
T2 Average EXIT DD -2.88 % 1.63 % 13.86 % -0.86 % 8.85 %
Table 6.5: DDs between measured diode doses and Monaco modelled doses for similar points in RANDO,
averaged from the left and right fields for both T1 and T2. Green where DD < 3 %, yellow where DD
< 6 %, red where DD > 6 %.
It is shown in Table 6.5 that the averaged entrance doses have good agreement between measurement
and Monaco for all regions. For exit doses however, the chest and groin exit doses exceed the clinically
acceptable dose difference. The DD in approximate peak lung dose is 1.756 % and 7.096 % for T1 and
T2 respectively. These DDs show Monaco underestimates the peak lung dose for both linacs, for T1 the
DD is within clinically acceptable agreement, however for T2 no clinically acceptable agreement exists
for the approximate peak lung dose. It is important to note that what is called the peak lung dose is
not actually within the lung but rather the dose at the surface of the skin closest to the lung (armpit).
This means the "peak lung dose" is an overestimate of the true peak lung dose and therefore this being
underestimated is not necessarily an issue clinically as may actually be more representative of the true
peak lung dose which would be less than the dose at the surface closest to the lung. Additionally we
can see the difference is not too far from clinical significance (only 1.096 % off) and this difference in
representation (being an additional few centimeters of skin) could actually make up this difference,
meaning that this underestimation may be acceptable when additional depth is considered.
There are a few potential reasons why the chest and groin exit doses have significant dose dis-
crepancies between Monaco and diode measurements. These include those mentioned in Sec. 6.2.1,
additionally since diodes require an orientation correction factor with an orientation representative of
the diode position during measurement, if the diodes during measurement had deviated slightly (due to
rice bag packing and placement) this could have had a significant affect on the final measured results
for the exit diodes. Ultimately it is unclear why only the chest and groin exit results were not clinically
acceptable, this highlights an opportunity for further investigation of diode orientation and measured
diode results when using the RANDO phantom.
6.2.3 Farmer Chamber Comparison
The midline groin doses measured with the farmer chamber in Sec. 5.5.3 are compared with those
calculated using Monaco in Sec. 4.2.2.3. These are compared by their DDs using Eq. 2.17 where D1
Chapter 6. Discussion 82
are the measured doses and D2 are Monaco calculated doses for the left field. These DDs are shown
below for both T1 and T2 treatment rooms:
DD(T1) = 0.978 %,
DD(T2) = 0.935 %.
The small differences in groin dose show a strong, clinically acceptable agreement between the
measured and Monaco calculated doses for the left field. Additionally whilst these DDs were only
determined for the left fields (since the farmer chamber measurements were only carried out using the
left field), it can be seen by inspecting the doses in Sec. 5.5.3 and Sec. 4.2.2.3 that the maximum
difference in dose does not exceed 6 %, even if the left field doses are compared with the right field
doses. Farmer chamber results are regarded as the most reliable clinically (as uncertainties are well
understood) and therefore agreement results have more weight than the diode of film results in terms
of supporting the Monaco model results validity.
6.2.4 Spreadsheet Comparison
Spreadsheet midline doses were compared with Monaco midline doses in Sec. 4.2.2.4, it was found that
with the exception of one dose (which existed in the penumbra region), that the spreadsheet had a clini-
cally acceptable agreement with Monaco. Just because the two calculation methods agree however does
not mean that they necessarily agree with measurement. This section compares spreadsheet calculated
doses with measured midline doses from Ch. 5 to evaluate the spreadsheet and discuss with respect to
Monaco midline DDs from Sec. 6.2.1. DDs were calculated using Eq. 2.17 with D1 being film measured
or diode-interpolated midline doses and D2 the Monaco modelled dose.
Region
Comparison Head Neck Chest Umbilicus Groin
T1 Interpolated Diodes DD -50.049 % 2.878 % 6.730 % 6.510 % 12.099 %
T1 Film DD -13.766 % 2.085 % 2.645 % 5.774 % 15.506 %
T2 Interpolated Diodes DD 2.636 % 10.089 % 11.305 % 7.521 % 9.732 %
T2 Film DD 9.106 % -0.987 % 3.707 % 10.505 % 14.739 %
Table 6.6: DDs between interpolated diode and film measurements and spreadsheet calculated midline
doses for T1 and T2. Green where DD < 3 %, yellow where DD < 6 %, red where DD > 6 %.
DDs from Table 6.6 show few areas of clinically acceptable agreement with respect to midline doses.
The interpolated diode results and film results are not directly comparable (as the measurement positions
differ), so these results do not necessarily show a discrepancy between the measured results themselves,
but rather highlights the fact that inhomogeneities are not considered with the existing spreadsheet
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since these DDs between film and diode for T1 and T2 should be closer together if inhomogeneities were
considered with the spreadsheet.
For T1 the large DD from the head is expected, as this is within the penumbral region, however the
discrepancies outside of this region which result in several regions not being within clinically acceptable
agreement are concerning. The film DDs do validate the use of the spreadsheet for the calculation of
lung doses, though unfortunately for every point of agreement (the exception being the T1 neck DD)
with one measurement type, there seems to be a contradicting point of disagreement from the other
measurement type. This makes it very difficult to make an accurate conclusion based on this alone.
The groin dose was also similarly compared with Farmer chamber measurements made and DDs
were found to be:
DD(T1) = −2.622 %,
DD(T2) = −0.558 %.
These DDs indicate the spreadsheet has clinically acceptable agreement between measured and
modelled results for the groin midline, this differs from Table 6.6 where midline doses for the groin
region had no clinical agreement whatsoever. As discussed earlier the positions of measurement devices
differed and therefore are not directly comparable. These differences may have more to do with how
the spreadsheet deals with changes in positions and lack of inhomogeneity consideration.
The peak lung dose was also compared with averaged diode measurements from Sec. 5.5.2, the DDs
were determined to be:
DD(T1) = 6.624 %,
DD(T2) = 8.159 %.
With respect to the peak lung DDs above, no clinically acceptable agreement exists for either T1
or T2. The spreadsheet underestimates the peak lung dose significantly more than Monaco does (in
Sec. 6.2.2). Overall the spreadsheet shows poor agreement with measurement with the Farmer chamber
measurement being the exception. The spreadsheet calculation has fewer regions which are within
clinically acceptable agreement than Monaco. It is important to note that what is considered to be the
peak lung dose is not actually within the lung but rather the dose at the surface of the skin closest to
the lung (armpit). This means what we call the peak lung dose is an overestimate of the true peak
lung dose and therefore this being underestimated is not necessarily an issue clinically as may actually
be more representative of the true peak lung dose which would be less than the dose at the surface
closest to the lung. Additionally we can see the difference is not too far from clinical significance (only
2 % to 3 % off) and this difference in representation (being an additional few centimeters of skin) could
actually make up this difference, meaning that this underestimation could be technically acceptable as
it considers additional depth.
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Overall it is unclear exactly why the spreadsheet results are not clinically acceptable when compared
with film and diode measurements however are clinically acceptable when compared with the Farmer
chamber results. It is possible measurement and setup errors, or lack of inhomogeneity modelling (both
discussed in Sec. 6.2.1) may be responsible for some of these differences, however at this stage this is
unclear. Farmer chamber results are considered to have the most dosimetric confidence with respect to
absolute dose because they are calibrated and used often with limitations well understood. Interestingly
the fact that the Farmer chamber measurements agree well with both Monaco and the spreadsheet where
film and diodes fail adds significant complications in discussing results appropriately, it does however
provide a clear path for future work which can be done to improve results and comparisons made.
6.2.5 Summary
There are several points of clinically acceptable agreement and disagreement between measured and
Monaco determined point doses. Results do not definitively show whether Monaco can determine
clinically acceptable doses for the key interest regions in a patient. There have been several potential
reasons provided as to why dose difference results do not clearly show in all regions clinically acceptable
agreement between measured and modelled doses both in Monaco and with the existing spreadsheet.
Although several reasons have been provided, ultimately it is unclear why results do not agree, the
spreadsheet in particular has been used at Christchurch Hospital for several years, and there have been
no reported issues from ROs or physicists in terms of toxicities like interstitial penumonitis arising from
overdoses, or ineffective treatments from underdoses. The uncharacterisable disagreement between diode
and film measured and modelled results, and strong agreement between Farmer chamber measured and
modelled results show a clear need for further investigation of doses for clinical recommendations to be
made.
Whilst no issues have been reported with the current technique thus far, accurate dosimetry for
TBI using treatment planning systems is still necessary to allow for patient specific modelling of dose
distributions. This will bring the TBI treatment approach into line with other modern radiation therapy




The work in this thesis was driven by two main goals. One was to develop and validate a PMD for im-
proving the accuracy of profile and TPR acquisition under eSSD TBI conditions. This has been achieved
by discussing and building the device with the UC workshop, validating necessary dosimetry equipment,
developing software for automatic profile acquisition, and characterizing the scatter introduced by the
PMD.
In Ch. 3 we presented the purpose, design and evaluation of the PMD and relevant dosimetry
equipment. Evaluation showed that the temporal resolution of the electrometer was approximately
0.5 s, which was incorporated into the TBIControl software. The PMD in both T1 and T2 was shown to
contribute no measurable scatter to a point in a solid water phantom given the measurement uncertainty
as is shown by in-air measurement. These characterizations were important to consider when the PMD
is used for measurement of profiles and TPRs. Successful measurements of profiles and TPRs were then
conducted using the PMD in Ch. 5 and it was shown to be an effective device at significantly reducing
the total TBI commissioning measurement time by an order of magnitude, and reducing the uncertainty
of measurement point localization from ±2 cm to ±1 mm (95 % confidence interval).
The second goal of this work was to evaluate the Monaco TPS and the existing spreadsheet treat-
ment planning in TBI conditions. This was achieved by comparing Monaco and the spreadsheet with
measurements in both simple block-phantom geometries and in a complex anthropomorphic phantom.
To do accurate comparisons, several quantities were needed to be both measured and determined, these
included wall scatter and diode orientation factors to name a couple.
Ch. 4 presented the necessary introduction, methodology and results evaluating the MC and CCC
models in Monaco at eSSD with block-like phantoms. It was found at this stage that the MC model
was unsuitable for eSSD as the model was noisy and produced profiles and TPRs which qualitatively
looked irregular. Following from this, a CT of the anthropomorphic RANDO phantom was imported
with point doses determined for comparison to measured results. Finally a brief comparison between
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midline doses calculated using the existing spreadsheet and Monaco showed all but one region were
within clinically acceptable agreement with one other, there a couple of significant differences in a few
regions.
Measurements for comparison were presented in Ch. 5. Methods, results and discussion for the
measurement of dose in both block-like and anthropomorphic phantoms was provided, along with the
measurement of wall scatter and diode orientation factor as correction quantities so that an accurate
comparison to modelled results could be given. Comparisons between measured results and treatment
planning results were then presented in Ch. 6. The complete quantitative comparison given as DDs were
shown to effectively determine the agreement between measured and modelled results in both simple
block-like phantoms, and complex anthropomorphic phantoms. Comparisons show that for the simple
block-like homogeneous phantom, that the existing Monaco CCC model is within 6 % DD between
measured and modelled results over the clinically useful field size for T1. For T2 however the model
only validates to 6 % in the depth range between 5 cm to 50 cm which is an acceptable constraint for
the majority of TBI treatments.
Comparisons to point doses using inhomogeneous anthropomorphic phantoms were the next step
once results in homogeneous block phantoms were determined to be clinically acceptable. DD results
showed that whilst Monaco seemed to outperform the spreadsheet for various areas, there were still
many points where Monaco seemed to disagree with measured results. The point dose measurements in
RANDO using the film and diodes were logistically challenging and due to time and resource constraints
a larger array of measurements could not be done, these likely could have been reasons for some of
the points of disagreement where measurements may not have been performed perfectly. Overall it was
unclear why disagreements exist, though there are several areas to investigate which include comparisons
with past patient data, remeasuring depth doses in RANDO using a Farmer chamber, the uncertainties
associated with changes in amounts of rice bag material, and diode orientation uncertainty with respect
to angular differences between the determined orientation factor diode positions and measurement diode
positions. At this stage clinical recommendations with respect to the use of Monaco as a TPS for eSSD
TBI treatment planning cannot be definitively made, comparison of results indicates an opportunity for
further investigation in anthropomorphic phantoms.
Future Prospects
The next logical step in this work would be to re-evaluate dose differences between Monaco and mea-
surement with anthropomorphic phantoms. Rather than measuring point doses, several large 2D dose
maps could be measured with pieces of film cut to fit entire RANDO slices, which would allow for a
simple overlay comparison of measured and modelled results and direct comparison of measurements
made with different dosimetric approaches. The use of a Farmer chamber rather than diodes for mea-
suring entrance and exit doses whilst significantly more time-consuming, would provide superior results
with greater confidence to improve upon accuracy of comparisons to Monaco.
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Next investigating the depth dose uncertainty with respect to rice bag packing efficiency would
provide a clear idea of how significantly differently sized air gaps within and between the rice bags impact
the depth dose for various regions in RANDO. This would likely be best done using Farmer chambers for
greater confidence in measurements made. Results would provide a quantitative uncertainty associated
with the rice bag packing efficiency during measurement rather than an estimated inefficiency built into
the model.
The RANDO phantom is not a perfect representation of a patient and measured doses may have
been affected by the physical difficulty in packing rice bags due to the hard phantom material and spoiler
positions. In practice, rice bag packing is significantly more efficient due to the rice bags conforming
easily with the patient’s body. Using past and future patient CT data in comparison to in-vivo mea-
surements made during treatments could provide better comparisons between measured and modelled
data.
There are a couple of other quantities which would be of interest to investigate. Angular deviations
in diode orientation in measurement may mean the orientation factor may not apply correctly to all
diodes, especially when curvature (and thus possible angular deviation of the measurement diode) of
RANDO depends on diode location. Quantifying the change in orientation factor with respect to an-
gular deviations < 30◦ and measuring the approximate angular deviation from the orientation factor
measurement position of the diode in measurement would provide a more appropriate orientation factor
for diodes at their respective positions on RANDO and therefore providing greater measurement accu-
racy. In Sec. 5.3 the reasoned assumption was made that wall scatter does not need to be considered
for Monaco comparison with the anthropomorphic phantom due to rice bag packing and beam spoilers.
It would increase the measurement certainty to measure quantitatively whether wall scatter under full
TBI patient conditions is significant or not, and therefore whether this negligibly assumption holds true.
Further investigating these potential sources of uncertainty in measurement provides a clear path
towards acquiring results with improved accuracy and clinical confidence. These improvements will
allow for appropriate clinical recommendations to be made as to whether Monaco can be used as a
treatment planning system for TBI treatments at Christchurch Hospital.
Appendix A
Best practices for TBI measurements
using the Phantom Mobility Device
Using Solid Water
1. Align farmer chamber to shallowest depth first (i.e. 2cm)
2. Use 50 % Blue SW and 50 % Brown SW.
3. Solid water being stacked from front to back should be stacked in additive amounts which sum
up to subsequent depths, i.e. if our measurements are 2 cm, 5 cm, 10 cm, 20 cm, 30 cm then solid
water should be stacked (from front to back): 10 cm, 10 cm, 5 cm, 3 cm. This is illustrated by Fig.
A.1.
4. Initially 2 cm should be aligned at the centre of the wooden holding tray, this is so that when
Solid water is stacked from the back to the front, it can be added up to 30 cm in total without
exceeding the bounds of the tray.
5. For depths greater than 30 cm depth, the 30 cm× 30 cm× 30 cm block of water should be used
with the chamber block (and up to 10 cm of material including the chamber block) behind the
water block, this allows for 40 cm depth + 20 cm depth (up to 60 cm depth) to be done in a single
re-align (single realigning from 30 cm× 30 cm× 30 cm to up to 60 cm× 30 cm× 30 cm). This is
illustrated by Fig. A.2.
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Figure A.1: Solid water set up for up to 30 cm depth.
Figure A.2: Solid water and water block set up for measurement depths greater than 30 cm.
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Equipment Set-up
1. Set PMD on top of TBI Treatment couch, pushing the corner of the PMD to one of the corners
of the TBI couch (and ensuring it stays in this position by pushing it back into the corner when
making any changes like moving the couch). The reason this is done is to make sure that the posi-
tion of the PMD and phantom with respect to the PMD and couch frame are constant throughout
measurement and do not become skewed, this allows for quicker repeatability of measurement (as
you do not need to continually check alignment once initially aligned) and ensures consistency.
2. Align the PMD with the central axis using the red and green room lasers, align the red laser to the
black marked lines which run from end to end of the PMD and through the Solid water holding
tray.
3. Plug the leads for the drive and termination points into the PMD from the PMD drive box.
4. Plug the long (coiled) RS232 lead into the PMD drive box and into the computer (using the
green/grey RS232 to USB Cable).
5. Plug the Electrometer into the PC using the black RS232 cable.
Beam Control
1. Ensure that T-CTRL mode is used to overcome the 1000 MU limit interlock, such that measure-
ment for long periods (required by the software) can take place, and set Total MU to 9999.
2. Make sure to wait 2 minutes (T2) to 4 minutes (T1) after beam turned on (for T1 and T2 to allow
for drifting) before starting each measurement.
3. Once measurements are complete make sure Interlock override has been turned off.
TBIControl Software
A.4.1 Step and Record Mode
1. Select the RS232 ports for the PMD and Electrometer respectively, once connected these should
output their model thus allowing you to check you have connected the correct one under the right
heading.
2. At the top left hand corner there is a drop down menu, from this select "Step and Record".
3. Specify the PMD Speed (Speed at which the device will move at), time period to record at each
step, start position (start position of the PMD), final position and PMD step, and if required
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specifying the CAX Position (If this is unspecified it will use the Start position as the CAX
Position).
4. Specify the record depths (depths of the chamber to record at), separated by commas.
5. Click Initialize to Initialize the PMD and Zero the electrometer
6. Click "Start", this will re-initialize the PMD and then begin to measure starting at the first depth
to record, make sure the beam is ON at this point.
7. At each depth, post measurement it will ask if the measurement has been successful, if there
has been a problem with the beam mid-measurement (I.e. Unexpected termination), then wait
for this profile measurement to complete, re-run the beam and select "No", this will cause the
measurement for the depth to be repeated. If there has been no problems select yes.
8. After selecting yes, the PMD will reinitialize to the CAX point, this will allow for the setup of the
water block/solid water for the next measurement depth. Once you have it set up for the next
depth, and are ready to go make sure turn the beam back on for 2 minutes (T2) to 4 minutes
(T1), to allow for drifting, then hit "OK" on a message box that will prompt asking If it is ready
for the next depth.
9. Recommended: Terminate and Redo the beam at each depth or two, in order to make sure that
the beam does not reach the MU Limit before the profile measurement completes.
10. Once Measurement complete it will prompt advising this, and will save the data in Json for-
mat locally, it will also appear beneath the "Initialize" Button in the Format of SRsave-
DDMMYYYYhhmmss (Day Month Year hour minute second).
A.4.1.1 Plotting Controls
• Plotting controls provide a means of a "quick check" of TPRs and Profiles such that one can see
if these qualitatively "look right". They do not currently provide statistical analysis and therefore
should not be used in lieu of such.
• You can click on the data set (SRsave- or CRsave- depending on Step and Record or Continuous
Record), Once clicked on a number of check boxes should show for plotting various OADs/Depths,
select those you wish to plot and then click on "Plot Data", this will plot the respective TPRs
and Profiles into two graphs.
• There is a normalization control allowing for the normalization of the profiles/TPRs to a specific
depth and off-axis position, this can be specified by ticking the "Normalize" box and specifying the
depth and off axis Distance to normalize to (a default one for each will be automatically selected).
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A.4.2 Individual Electrometer Measurements
1. Select "Electrometer Read" from upper left hand corner dropdown menu
2. Input Time period to record for in seconds.
3. Wait 2 minutes (T2) to 4 minutes (T1) after beam on to allow for drifting.
4. Click "Read", this will read the dose rate every time the buffer updates (or has been more than
the buffer update / "temporal resolution" time), and once complete will output the charge rates
recorded, the average charge rate, and the standard deviation.
A.4.3 Individual PMD Movement
1. Select "Move PMD" from upper left hand corner dropdown menu.
2. Click Initialize to Initialize the PMD
3. Input the distance to move the PMD by (in mm)
4. Input the speed (in mm/s)
5. Input the movement mode;
• Absolute move drives the PMD to move to/by distance specified.
• Relative move either adds or subtracts the move to/by distance from the current distance
and drives the PMD to this position.
• Drive out drives the PMD out to the maximum distance.
• Drive in drives the PMD in to the minimum distance (nominally 0).
Appendix B
Expression and Evaluation of
Uncertainty
Uncertainty in measurement is an important subject to discuss, especially when comparing results and
drawing conclusions. The guide to the expression of uncertainty in measurement (GUM)54 provides a
rigorous framework for the evaluation and expression of uncertainties. This framework includes both the
expression of absolute and relative uncertainties along with the determination of combined uncertainty
for a measured quantity.
The GUM establishes two primary types of uncertainty, type A and type B uncertainties. Type A
uncertainties are any uncertainties obtained by statistical analysis of a sample of measurements, these
can typically be reduced by increasing the sample size of measurements taken. Type B uncertainties
are obtained by any other means than measurement.
Type A Uncertainties
The statistical determination of uncertainty relies upon a sample including multiple measurements
of a quantity. These measurements can be averaged over the number of total measurements taken
providing the arithmetic mean, the standard deviation or spread of values can then be determined from
the differences between each data point and the mean. Suppose we have some measured quantity x













(xi − x̄)2 (B.2)
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Finally an experimental standard deviation can be determined, which is an estimate of how far the
sample mean is likely to be from the population mean, and therefore how representative the mean of our
measurement is in relation to all possible measurements in the population. The experimental standard





When working with data set where data points are normalized by another given data point, the rela-
tive uncertainty (ur) is a useful quantity as it allows for the calculation of uncertainty of the normalized





This thesis relies upon the determination of normalized profiles and TPRs, the relative uncertainty is
therefore useful in the determination of the associated uncertainties, therefore allowing for appropriate
discussion and conclusions to be drawn from analysed data. Finally the type A uncertainty, whether
relative or absolute will be expressed as the quantity uA.
Type B Uncertainties
Type B uncertainties are those not calculated through statistical analysis. Instead they can only be
estimated from a variety of sources. These include manufacturers specifications, data provided in cali-
bration certificates, experience with or general knowledge of the behaviour and properties of materials
and instruments, uncertainties from reference data in literature, etc. Type B uncertainties can be re-
duced by improvement in equipment, better understanding of measurement apparatus and setup. The
estimated type B uncertainties for a measurement is expressed as the quantity uB .
Combined Uncertainty
Given that no correlation exists between type A and type B uncertainties for a particular set of mea-
surements, these can be combined in quadrature to determine total measurement uncertainty. This






It is important to note that if uA is expressed as a relative uncertainty, then uB must also be
expressed as a relative uncertainty. Then the total absolute uncertainty uc is computed by multiplying
the combined relative uncertainties by the mean value of quantity measured. Throughout this thesis,
the uncertainty in measured quantities is either determined or assumed to be based on a gaussian











import matplotlib.pyplot as plt
rm = visa.ResourceManager()
print(rm.list_resources())
comport = input("Please input COM Number from list above i.e. for ASRLCOM5::INSTR the COM number is 5: ")
inst = rm.open_resource("ASRLCOM"+str(comport)+"::INSTR",baud_rate = 19200)




starttime = time.time() # Starting time in s
start = inst.query("STA")
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drdata = inst.query("D1") #Dose rate query






charge = numpy.array(charge) ∗ (10∗∗9) # Convert charge from C to nC
current = numpy.array(current) ∗ (10∗∗9) # Convert current from A to nA











plt.title(’Charge vs time with 3.3 Hz Square Wave Signal 3Vpp amplitude’)
plt.show()
Appendix D
TBIControl Source Code Release
The TBIControl software developed during this project is open-source. The entire code base was written
over a one week period and is therefore not perfectly optimized in terms of multi-threading and code
abstraction. There are thousands of lines of code which have been written and as such have been
committed to a Github repository for full access of the code and compiled binary application. I fully
support any centres/individuals who wish to use and extend/improve the code and therefore will keeping
up to date with any pull requests submitted and merging changes appropriately. The release and source
code can be found at: https://github.com/Phillip-Duncan/TBIControl/releases.
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